Predictive Oncology (POAI) S-1/A 10 Jan 17 2016 Q3 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 30, 2016
Document Information [Line Items]
Entity Registrant Name	Skyline Medical Inc.
Entity Central Index Key	1,446,159
Trading Symbol	skln
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		3,804,860
Document Type	S-1/A
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	true
Amendment Description	Amendment effecting a 1:25 reverse stock split to Form 10-Q for period ended 9/30/16.

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Series A Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 10,000,000 authorized, 0 and 20,550 outstanding		$ 206
Series B Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 10,000,000 authorized, 0 and 20,550 outstanding	18,950
Cash	4,856,232	16,384
Accounts Receivable	38,283	57,549
Inventories	231,740	367,367
Prepaid Expense and other assets	271,579	190,015
Total Current Assets	5,397,834	631,315
Fixed Assets, net	139,598	196,479
Intangibles, net	94,987	73,183
Total Assets	5,632,419	900,977
Accounts Payable	650,413	2,194,518
Accrued Expenses	864,295	3,066,379
Short-term notes payable net of discounts of $0 and $194,097 (See Note 4)		937,424
Deferred Revenue	5,000	5,000
Total Current Liabilities	1,519,708	6,203,321
Accrued Expenses		213,883
Liability for equity-linked financial instruments (See Note 8)
Total Liabilities	1,519,708	6,417,204
Commitments and Contingencies
Common Stock, $.01 par value, 4,000,000 authorized, 208,259 and 123,711 outstanding	2,080	1,237
Additional paid-in capital	44,584,118	30,123,435
Accumulated deficit	(40,492,437)	(35,641,105)
Total Stockholders' Equity (Deficit)	4,112,711	(5,516,227)
Total Liabilities and Stockholders' Equity (Deficit)	$ 5,632,419	$ 900,977

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	20,550
Preferred stock, stated value (in dollars per share)	$ 100	$ 100
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	1,895,010	0
Discount on short-term notes payable	$ 0	$ 194,097
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000	4,000,000
Common stock, shares outstanding (in shares)	208,259	123,711

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 134,605	$ 85,792	$ 316,931	$ 471,078	$ 654,354	$ 951,559
Cost of goods sold	26,481	19,773	149,130	199,307	303,982	385,323
Gross Margin	108,124	66,019	167,801	271,771	350,372	566,236
General and administrative expense	733,074	861,098	4,684,130	1,589,522	3,399,339	4,882,549
Operations expense	292,856	202,799	928,062	375,429	846,687	972,830
Sales and marketing expense	137,784	66,720	348,848	439,703	503,989	1,178,305
Interest expense	3	51,804	3	394,641	390,887	377,719
Loss (gain) on valuation of equity-linked financial instruments						(11,599)
Total expense	1,163,717	1,182,421	5,961,043	2,799,295	5,140,902	7,399,804
Net loss available to common shareholders	$ (1,055,593)	$ (1,116,402)	$ (5,793,242)	$ (2,527,524)	$ (4,790,530)	$ (6,833,568)
Loss per common share - basic and diluted (in dollars per share)	$ (0.32)	$ (7.09)	$ (2.57)	$ (18.39)	$ (30.86)	$ (57.13)
Weighted average shares used in computation - basic and diluted (in shares)	3,320,139	157,445	2,250,315	137,428	155,233	119,619

Statement of Stockholders Equit

Statement of Stockholders Equity - USD ($)	Warrant Exercisable At $375.00 Per Share [Member]Preferred Stock [Member]	Warrant Exercisable At $375.00 Per Share [Member]Common Stock [Member]	Warrant Exercisable At $375.00 Per Share [Member]Additional Paid-in Capital [Member]	Warrant Exercisable At $375.00 Per Share [Member]Retained Earnings [Member]	Warrant Exercisable At $375.00 Per Share [Member]	Option Exercisable at $31.25 [Member]Preferred Stock [Member]	Option Exercisable at $31.25 [Member]Common Stock [Member]	Option Exercisable at $31.25 [Member]Additional Paid-in Capital [Member]	Option Exercisable at $31.25 [Member]Retained Earnings [Member]	Option Exercisable at $31.25 [Member]	Shares Issued at $515.75 [Member]Preferred Stock [Member]	Shares Issued at $515.75 [Member]Common Stock [Member]	Shares Issued at $515.75 [Member]Additional Paid-in Capital [Member]	Shares Issued at $515.75 [Member]Retained Earnings [Member]	Shares Issued at $515.75 [Member]	Warrant Exercisable at $318.75 [Member]Preferred Stock [Member]	Warrant Exercisable at $318.75 [Member]Common Stock [Member]	Warrant Exercisable at $318.75 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $318.75 [Member]Retained Earnings [Member]	Warrant Exercisable at $318.75 [Member]	Option Exercisable at $131.25 [Member]Preferred Stock [Member]	Option Exercisable at $131.25 [Member]Common Stock [Member]	Option Exercisable at $131.25 [Member]Additional Paid-in Capital [Member]	Option Exercisable at $131.25 [Member]Retained Earnings [Member]	Option Exercisable at $131.25 [Member]	Warrant Exercisable at $18.75 [Member]Preferred Stock [Member]	Warrant Exercisable at $18.75 [Member]Common Stock [Member]	Warrant Exercisable at $18.75 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $18.75 [Member]Retained Earnings [Member]	Warrant Exercisable at $18.75 [Member]	Warrant Exercisable at $337.50 [Member]Preferred Stock [Member]	Warrant Exercisable at $337.50 [Member]Common Stock [Member]	Warrant Exercisable at $337.50 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $337.50 [Member]Retained Earnings [Member]	Warrant Exercisable at $337.50 [Member]	Shares Issued at $468.75 [Member]Preferred Stock [Member]	Shares Issued at $468.75 [Member]Common Stock [Member]	Shares Issued at $468.75 [Member]Additional Paid-in Capital [Member]	Shares Issued at $468.75 [Member]Retained Earnings [Member]	Shares Issued at $468.75 [Member]	Warrant Exercisable at $187.50 [Member]Preferred Stock [Member]	Warrant Exercisable at $187.50 [Member]Common Stock [Member]	Warrant Exercisable at $187.50 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $187.50 [Member]Retained Earnings [Member]	Warrant Exercisable at $187.50 [Member]	Warrant Exercisable at $140.75 [Member]Preferred Stock [Member]	Warrant Exercisable at $140.75 [Member]Common Stock [Member]	Warrant Exercisable at $140.75 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $140.75 [Member]Retained Earnings [Member]	Warrant Exercisable at $140.75 [Member]	Warrant Exercisable at $318.75 2 [Member]Preferred Stock [Member]	Warrant Exercisable at $318.75 2 [Member]Common Stock [Member]	Warrant Exercisable at $318.75 2 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $318.75 2 [Member]Retained Earnings [Member]	Warrant Exercisable at $318.75 2 [Member]	Shares Issued at $487.50 [Member]Preferred Stock [Member]	Shares Issued at $487.50 [Member]Common Stock [Member]	Shares Issued at $487.50 [Member]Additional Paid-in Capital [Member]	Shares Issued at $487.50 [Member]Retained Earnings [Member]	Shares Issued at $487.50 [Member]	Warrant Exercisable at $281.25 [Member]Preferred Stock [Member]	Warrant Exercisable at $281.25 [Member]Common Stock [Member]	Warrant Exercisable at $281.25 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $281.25 [Member]Retained Earnings [Member]	Warrant Exercisable at $281.25 [Member]	Shares Issued at $281.25 [Member]Preferred Stock [Member]	Shares Issued at $281.25 [Member]Common Stock [Member]	Shares Issued at $281.25 [Member]Additional Paid-in Capital [Member]	Shares Issued at $281.25 [Member]Retained Earnings [Member]	Shares Issued at $281.25 [Member]	Shares Issued at $468.75 2 [Member]Preferred Stock [Member]	Shares Issued at $468.75 2 [Member]Common Stock [Member]	Shares Issued at $468.75 2 [Member]Additional Paid-in Capital [Member]	Shares Issued at $468.75 2 [Member]Retained Earnings [Member]	Shares Issued at $468.75 2 [Member]	Warrant Exercisable at $337.50 2 [Member]Preferred Stock [Member]	Warrant Exercisable at $337.50 2 [Member]Common Stock [Member]	Warrant Exercisable at $337.50 2 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $337.50 2 [Member]Retained Earnings [Member]	Warrant Exercisable at $337.50 2 [Member]	Shares Issued at $487.50 2 [Member]Preferred Stock [Member]	Shares Issued at $487.50 2 [Member]Common Stock [Member]	Shares Issued at $487.50 2 [Member]Additional Paid-in Capital [Member]	Shares Issued at $487.50 2 [Member]Retained Earnings [Member]	Shares Issued at $487.50 2 [Member]	Warrant Exercisable at $243.75 [Member]Preferred Stock [Member]	Warrant Exercisable at $243.75 [Member]Common Stock [Member]	Warrant Exercisable at $243.75 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $243.75 [Member]Retained Earnings [Member]	Warrant Exercisable at $243.75 [Member]	Warrant Exercisable at $140.75 2 [Member]Preferred Stock [Member]	Warrant Exercisable at $140.75 2 [Member]Common Stock [Member]	Warrant Exercisable at $140.75 2 [Member]Additional Paid-in Capital [Member]	Warrant Exercisable at $140.75 2 [Member]Retained Earnings [Member]	Warrant Exercisable at $140.75 2 [Member]	Option Exercisable at $131.25 2 [Member]Preferred Stock [Member]	Option Exercisable at $131.25 2 [Member]Common Stock [Member]	Option Exercisable at $131.25 2 [Member]Additional Paid-in Capital [Member]	Option Exercisable at $131.25 2 [Member]Retained Earnings [Member]	Option Exercisable at $131.25 2 [Member]	Note Conversion at $167.00 [Member]Preferred Stock [Member]	Note Conversion at $167.00 [Member]Common Stock [Member]	Note Conversion at $167.00 [Member]Additional Paid-in Capital [Member]	Note Conversion at $167.00 [Member]Retained Earnings [Member]	Note Conversion at $167.00 [Member]	Note Conversion at $167.00 2 [Member]Preferred Stock [Member]	Note Conversion at $167.00 2 [Member]Common Stock [Member]	Note Conversion at $167.00 2 [Member]Additional Paid-in Capital [Member]	Note Conversion at $167.00 2 [Member]Retained Earnings [Member]	Note Conversion at $167.00 2 [Member]	Note Conversion at $146.25 [Member]Preferred Stock [Member]	Note Conversion at $146.25 [Member]Common Stock [Member]	Note Conversion at $146.25 [Member]Additional Paid-in Capital [Member]	Note Conversion at $146.25 [Member]Retained Earnings [Member]	Note Conversion at $146.25 [Member]	Note Conversion at $125.75 [Member]Preferred Stock [Member]	Note Conversion at $125.75 [Member]Common Stock [Member]	Note Conversion at $125.75 [Member]Additional Paid-in Capital [Member]	Note Conversion at $125.75 [Member]Retained Earnings [Member]	Note Conversion at $125.75 [Member]	Shares Issued at $487.50 3 [Member]Preferred Stock [Member]	Shares Issued at $487.50 3 [Member]Common Stock [Member]	Shares Issued at $487.50 3 [Member]Additional Paid-in Capital [Member]	Shares Issued at $487.50 3 [Member]Retained Earnings [Member]	Shares Issued at $487.50 3 [Member]	Note Conversion at $128.50 [Member]Preferred Stock [Member]	Note Conversion at $128.50 [Member]Common Stock [Member]	Note Conversion at $128.50 [Member]Additional Paid-in Capital [Member]	Note Conversion at $128.50 [Member]Retained Earnings [Member]	Note Conversion at $128.50 [Member]	Note Conversion at $125.00 [Member]Preferred Stock [Member]	Note Conversion at $125.00 [Member]Common Stock [Member]	Note Conversion at $125.00 [Member]Additional Paid-in Capital [Member]	Note Conversion at $125.00 [Member]Retained Earnings [Member]	Note Conversion at $125.00 [Member]	Note Conversion at $131.50 [Member]Preferred Stock [Member]	Note Conversion at $131.50 [Member]Common Stock [Member]	Note Conversion at $131.50 [Member]Additional Paid-in Capital [Member]	Note Conversion at $131.50 [Member]Retained Earnings [Member]	Note Conversion at $131.50 [Member]	Note Conversion at $131.50 2 [Member]Preferred Stock [Member]	Note Conversion at $131.50 2 [Member]Common Stock [Member]	Note Conversion at $131.50 2 [Member]Additional Paid-in Capital [Member]	Note Conversion at $131.50 2 [Member]Retained Earnings [Member]	Note Conversion at $131.50 2 [Member]	Note Conversion at $148.75 [Member]Preferred Stock [Member]	Note Conversion at $148.75 [Member]Common Stock [Member]	Note Conversion at $148.75 [Member]Additional Paid-in Capital [Member]	Note Conversion at $148.75 [Member]Retained Earnings [Member]	Note Conversion at $148.75 [Member]	Note Conversion at $126.25 [Member]Preferred Stock [Member]	Note Conversion at $126.25 [Member]Common Stock [Member]	Note Conversion at $126.25 [Member]Additional Paid-in Capital [Member]	Note Conversion at $126.25 [Member]Retained Earnings [Member]	Note Conversion at $126.25 [Member]	Shares Issued at $487.50 4 [Member]Preferred Stock [Member]	Shares Issued at $487.50 4 [Member]Common Stock [Member]	Shares Issued at $487.50 4 [Member]Additional Paid-in Capital [Member]	Shares Issued at $487.50 4 [Member]Retained Earnings [Member]	Shares Issued at $487.50 4 [Member]	Shares Issued at $243.75 [Member]Preferred Stock [Member]	Shares Issued at $243.75 [Member]Common Stock [Member]	Shares Issued at $243.75 [Member]Additional Paid-in Capital [Member]	Shares Issued at $243.75 [Member]Retained Earnings [Member]	Shares Issued at $243.75 [Member]	Note Conversion at $72.50 [Member]Preferred Stock [Member]	Note Conversion at $72.50 [Member]Common Stock [Member]	Note Conversion at $72.50 [Member]Additional Paid-in Capital [Member]	Note Conversion at $72.50 [Member]Retained Earnings [Member]	Note Conversion at $72.50 [Member]	Note Conversion at $74.00 [Member]Preferred Stock [Member]	Note Conversion at $74.00 [Member]Common Stock [Member]	Note Conversion at $74.00 [Member]Additional Paid-in Capital [Member]	Note Conversion at $74.00 [Member]Retained Earnings [Member]	Note Conversion at $74.00 [Member]	Note Conversion at $72.75 [Member]Preferred Stock [Member]	Note Conversion at $72.75 [Member]Common Stock [Member]	Note Conversion at $72.75 [Member]Additional Paid-in Capital [Member]	Note Conversion at $72.75 [Member]Retained Earnings [Member]	Note Conversion at $72.75 [Member]	Note Conversion at $69.25 [Member]Preferred Stock [Member]	Note Conversion at $69.25 [Member]Common Stock [Member]	Note Conversion at $69.25 [Member]Additional Paid-in Capital [Member]	Note Conversion at $69.25 [Member]Retained Earnings [Member]	Note Conversion at $69.25 [Member]	Note Conversion at $56.25 [Member]Preferred Stock [Member]	Note Conversion at $56.25 [Member]Common Stock [Member]	Note Conversion at $56.25 [Member]Additional Paid-in Capital [Member]	Note Conversion at $56.25 [Member]Retained Earnings [Member]	Note Conversion at $56.25 [Member]	Note Conversion at $50.00 [Member]Preferred Stock [Member]	Note Conversion at $50.00 [Member]Common Stock [Member]	Note Conversion at $50.00 [Member]Additional Paid-in Capital [Member]	Note Conversion at $50.00 [Member]Retained Earnings [Member]	Note Conversion at $50.00 [Member]	Note Conversion at $56.82 [Member]Preferred Stock [Member]	Note Conversion at $56.82 [Member]Common Stock [Member]	Note Conversion at $56.82 [Member]Additional Paid-in Capital [Member]	Note Conversion at $56.82 [Member]Retained Earnings [Member]	Note Conversion at $56.82 [Member]	Note Conversion at $50.45 [Member]Preferred Stock [Member]	Note Conversion at $50.45 [Member]Common Stock [Member]	Note Conversion at $50.45 [Member]Additional Paid-in Capital [Member]	Note Conversion at $50.45 [Member]Retained Earnings [Member]	Note Conversion at $50.45 [Member]	Note Conversion at $48.10 [Member]Preferred Stock [Member]	Note Conversion at $48.10 [Member]Common Stock [Member]	Note Conversion at $48.10 [Member]Additional Paid-in Capital [Member]	Note Conversion at $48.10 [Member]Retained Earnings [Member]	Note Conversion at $48.10 [Member]	Note Conversion at $46.45 [Member]Preferred Stock [Member]	Note Conversion at $46.45 [Member]Common Stock [Member]	Note Conversion at $46.45 [Member]Additional Paid-in Capital [Member]	Note Conversion at $46.45 [Member]Retained Earnings [Member]	Note Conversion at $46.45 [Member]	Shares Issued at $243.75 3 [Member]Preferred Stock [Member]	Shares Issued at $243.75 3 [Member]Common Stock [Member]	Shares Issued at $243.75 3 [Member]Additional Paid-in Capital [Member]	Shares Issued at $243.75 3 [Member]Retained Earnings [Member]	Shares Issued at $243.75 3 [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2013																																																																																																																																																																																																																														$ 1,173	$ 25,477,788	$ (28,697,415)	$ (3,218,454)
Balance (in shares) at Dec. 31, 2013																																																																																																																																																																																																																														117,300
Series A warrant exercise		$ 1	$ 1,295		$ 1,296												$ 1	$ 2,492		$ 2,493							$ 1	$ 1,629		$ 1,630		$ 1	$ 35,999		$ 36,000							$ 2	$ 3,603		$ 3,605		$ 1	$ 2,332		$ 2,333		$ 0	$ 224		$ 224							$ 3	$ 52,497		$ 52,500												$ 1	$ 2,793		$ 2,794							$ 1	$ 1,057		$ 1,058		$ 4	$ 62,496		$ 62,500
Series A warrant exercise (in shares)		69															133										87					107										192					124					12										311															149										56					444
Shares issued for two options exercised at $65.75 per share							$ 2	$ 5,428		$ 5,430												$ 0	$ 1,400		$ 1,400																																																																								$ 0	$ 1,750		$ 1,750
Shares issued for two options exercised at $65.75 per share (in shares)							173															11																																																																											13
Shares Issued												$ 1	$ 41,249		$ 41,250																						$ 1	$ 24,999		$ 25,000																											$ 1	$ 23,999		$ 24,000		$ 1	$ 24,999		$ 25,000
Shares Issued (in shares)												80																									53																														85					53
Reduction in escrow account per settlement agreement																																																																																																																																																																																																																														$ (2)	(3,331)		(3,333)
Reduction in escrow account per settlement agreement (in shares)																																																																																																																																																																																																																														(178)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share																																																									$ 0	$ 18,919	$ (18,919)																							$ 1	$ 30,399	$ (30,400)																																						$ 1	$ 30,400	$ (30,401)																																	$ 1	$ 30,400	$ (30,402)	$ (1)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share (in shares)																																																									39																									62																																								62																																			62
Vesting Expense																																																																																																																																																																																																																															705,434		705,434
Options issued as part of employee bonus																																																																																																																																																																																																																															694,500		694,500
Shares issued in public offering; net																																																																																																																																																																																																																													206		2,054,795		2,055,001
Value of equity instruments issued with debt																																																																																																																																																																																																																															313,175		313,175
Shares issued for a note conversion																																																																																																						$ 1	$ 19,999		$ 20,000		$ 1	$ 19,999		$ 20,000		$ 1	$ 19,999		$ 20,000		$ 2	$ 19,998		$ 20,000							$ 2	$ 19,998		$ 20,000		$ 2	$ 19,998		$ 20,000		$ 2	$ 19,998		$ 20,000		$ 2	$ 29,998		$ 30,000		$ 2	$ 29,998		$ 30,000		$ 22	$ 280,594		$ 280,616
Shares issued for a note conversion (in shares)																																																																																																						121					121					137					156										156					160					152					228					202					2,223
Shares issued into an escrow account per settlement agreement																																																																																																																																																																																																																														$ 5	132		137
Shares issued into an escrow account per settlement agreement (in shares)																																																																																																																																																																																																																														548
Shares adjusted for rounding per reverse stock split																																																																																																																																																																																																																														$ 0	3		3
Shares adjusted for rounding per reverse stock split (in shares)																																																																																																																																																																																																																														8
Net loss																																																																																																																																																																																																																																(6,833,568)	(6,833,568)
Balance at Dec. 31, 2014																																																																																																																																																																																																																													206	$ 1,237	30,123,435	(35,641,105)	(5,516,227)
Balance (in shares) at Dec. 31, 2014																																																																																																																																																																																																																														123,711
Series A warrant exercise																																																																																																																																																																																																																														$ 1	9,899		9,900
Series A warrant exercise (in shares)																																																																																																																																																																																																																														120
Reduction in escrow account per settlement agreement																																																																																																																																																																																																																														$ (4)	(6,663)		(6,667)
Reduction in escrow account per settlement agreement (in shares)																																																																																																																																																																																																																														356
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share																																																																																																																																																																		$ 1	$ (1)																																																						$ 1	$ 30,401	$ (30,401)	$ 1
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share (in shares)																																																																																																																																																																		125																																																							125
Vesting Expense																																																																																																																																																																																																																															871,877		871,877
Shares issued in public offering; net																																																																																																																																																																																																																													16,667	667	13,043,546		13,060,880
Shares issued for a note conversion																																																																																																																																																																							$ 1	$ 9,999		$ 10,000		$ 3	$ 19,997		$ 20,000		$ 4	$ 29,996		$ 30,000		$ 5	$ 33,473		$ 33,478		$ 6	$ 34,994		$ 35,000		$ 14	$ 69,986		$ 70,000		$ 35	$ 199,965		$ 200,000		$ 6	$ 29,994		$ 30,000		$ 5	$ 24,995		$ 25,000		$ 6	$ 29,994		$ 30,000
Shares issued for a note conversion (in shares)																																																																																																																																																																							138					270					413					484					622					1,400					3,520					595					520					646
Net loss																																																																																																																																																																																																																																(4,790,530)	(4,790,530)
Balance at Dec. 31, 2015																																																																																																																																																																																																																													18,950	$ 2,080	44,584,118	(40,492,437)	4,112,711
Balance (in shares) at Dec. 31, 2015																																																																																																																																																																																																																														208,259
Shares issued in public offering; net (in shares)																																																																																																																																																																																																																														66,667
Preferred stock conversion																																																																																																																																																																																																																													2,077	$ 91	(2,168)		0
Preferred stock conversion (in shares)																																																																																																																																																																																																																														9,134
Series A warrant exercise																																																																																																																																																																																																																														$ 23,187	556,479		579,666
Series A warrant exercise (in shares)																																																																																																																																																																																																																														2,318,663
Shares issued for two options exercised at $65.75 per share																																																																																																																																																																																																																														$ 13	86,240		86,253
Shares issued for two options exercised at $65.75 per share (in shares)																																																																																																																																																																																																																														1,312
Vesting Expense																																																																																																																																																																																																																															147,158		147,158
Net loss																																																																																																																																																																																																																																(5,793,242)	(5,793,242)
Balance at Sep. 30, 2016																																																																																																																																																																																																																													792	$ 34,048	46,257,774	$ (46,285,679)	$ 11,514
Balance (in shares) at Sep. 30, 2016																																																																																																																																																																																																																														3,404,860
Preferred stock conversion																																																																																																																																																																																																																													$ (18,158)	$ 664	$ 17,494
Preferred stock conversion (in shares)																																																																																																																																																																																																																														66,396

Statement of Stockholders Equi6

Statement of Stockholders Equity (Parentheticals)	12 Months Ended
	Dec. 31, 2015$ / shares	Dec. 31, 2014$ / shares
Warrant Exercisable At $375.00 Per Share [Member]
Warrant exercise price (in dollars per share)		$ 375
Option Exercisable at $31.25 [Member]
Options exercise price (in dollars per share)		31.25
Shares Issued at $515.75 [Member]
Price of shares issued (in dollars per share)		515.75
Warrant Exercisable at $318.75 [Member]
Warrant exercise price (in dollars per share)		318.75
Option Exercisable at $131.25 [Member]
Options exercise price (in dollars per share)		131.25
Warrant Exercisable at $18.75 [Member]
Warrant exercise price (in dollars per share)		18.75
Warrant Exercisable at $337.50 [Member]
Warrant exercise price (in dollars per share)		337.50
Shares Issued at $468.75 [Member]
Price of shares issued (in dollars per share)		468.75
Warrant Exercisable at $187.50 [Member]
Warrant exercise price (in dollars per share)		187.50
Warrant Exercisable at $140.75 [Member]
Warrant exercise price (in dollars per share)		140.75
Warrant Exercisable at $318.75 2 [Member]
Warrant exercise price (in dollars per share)		$ 318.75
Shares Issued at $487.50 [Member]
Number of shareholders		16
Series A convertible preferred stock dividends (in dollars per share)		$ 487.50
Warrant Exercisable at $281.25 [Member]
Warrant exercise price (in dollars per share)		281.25
Shares Issued at $281.25 [Member]
Price of shares issued (in dollars per share)		281.25
Shares Issued at $468.75 2 [Member]
Price of shares issued (in dollars per share)		468.75
Warrant Exercisable at $337.50 2 [Member]
Warrant exercise price (in dollars per share)		$ 337.50
Shares Issued at $487.50 2 [Member]
Number of shareholders		16
Series A convertible preferred stock dividends (in dollars per share)		$ 487.50
Warrant Exercisable at $243.75 [Member]
Warrant exercise price (in dollars per share)		243.75
Warrant Exercisable at $140.75 2 [Member]
Warrant exercise price (in dollars per share)		140.75
Option Exercisable at $131.25 2 [Member]
Options exercise price (in dollars per share)		131.25
Note Conversion at $167.00 [Member]
Note conversion price (in dollars per share)		167
Note Conversion at $167.00 2 [Member]
Note conversion price (in dollars per share)		167
Note Conversion at $146.25 [Member]
Note conversion price (in dollars per share)		146.25
Note Conversion at $125.75 [Member]
Note conversion price (in dollars per share)		$ 125.75
Shares Issued at $487.50 3 [Member]
Number of shareholders		16
Series A convertible preferred stock dividends (in dollars per share)		$ 487.50
Note Conversion at $128.50 [Member]
Note conversion price (in dollars per share)		128.50
Note Conversion at $125.00 [Member]
Note conversion price (in dollars per share)		125
Note Conversion at $131.50 [Member]
Note conversion price (in dollars per share)		131.50
Note Conversion at $131.50 2 [Member]
Note conversion price (in dollars per share)		131.50
Note Conversion at $148.75 [Member]
Note conversion price (in dollars per share)		148.75
Note Conversion at $126.25 [Member]
Note conversion price (in dollars per share)		$ 126.25
Shares Issued at $487.50 4 [Member]
Number of shareholders		16
Series A convertible preferred stock dividends (in dollars per share)		$ 487.50
Shares Issued at $243.75 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Note Conversion at $72.50 [Member]
Note conversion price (in dollars per share)	72.50
Note Conversion at $74.00 [Member]
Note conversion price (in dollars per share)	74
Note Conversion at $72.75 [Member]
Note conversion price (in dollars per share)	72.75
Note Conversion at $69.25 [Member]
Note conversion price (in dollars per share)	69.25
Note Conversion at $56.25 [Member]
Note conversion price (in dollars per share)	56.25
Note Conversion at $50.00 [Member]
Note conversion price (in dollars per share)	50
Note Conversion at $56.82 [Member]
Note conversion price (in dollars per share)	56.82
Note Conversion at $50.45 [Member]
Note conversion price (in dollars per share)	50.45
Note Conversion at $48.10 [Member]
Note conversion price (in dollars per share)	48.10
Note Conversion at $46.45 [Member]
Note conversion price (in dollars per share)	$ 46.45
Shares Issued at $243.75 3 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (4,790,530)	$ (6,833,568)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	78,566	63,040
Vested stock options and warrants	871,877	723,367
Equity instruments issued for management and consulting	(6,667)	112,054
Amortization of debt discount	219,097	247,338
Penalty on debt provision	10,031
Loss on Sales of Equipment	17,076
Loss (gain) on valuation of equity-linked financial instruments		(11,599)
Changes in assets and liabilities:
Accounts receivable	19,266	39,696
Inventories	135,627	(245,192)
Prepaid expense and other assets	(81,564)	(129,427)
Accounts payable	(1,544,105)	1,132,410
Accrued expenses	(2,415,967)	1,594,468
Deferred Revenue		(64,000)
Net cash used in operating activities:	(7,487,293)	(3,371,413)
Cash flow from investing activities:
Purchase of fixed assets	(32,470)	(101,409)
Purchase of intangibles	(28,095)	(19,828)
Net cash used in investing activities	(60,565)	(121,237)
Cash flow from financing activities:
Proceeds from long-term and convertible debt	250,000	1,500,000
Principal payments on debt	(933,074)	(305,000)
Issuance of preferred stock	18,950	2,055,000
Issuance of common stock	13,051,830	157,081
Net cash provided by financing activities	12,387,706	3,407,081
Net increase (decrease) in cash	4,839,848	(85,569)
Cash and cash equivalents at beginning of period	16,384	101,953
Cash and cash equivalents at end of period	4,856,232	16,384
Non cash transactions:
Common stock issued for accrued interest/bonus		694,500
Common stock issued to satisfy debt	$ 483,478	$ 480,616

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 10,000,000 authorized, 0 and 20,550 outstanding	$ 792	$ 18,950
Cash and Cash Equivalents	634,478	4,856,232
Marketable Securities (Note 11)	576,888
Accounts Receivable	45,017	38,283
Inventories	289,249	231,740
Prepaid Expense and other assets	163,188	271,579
Total Current Assets	1,708,820	5,397,834
Fixed Assets, net	110,910	139,598
Intangibles, net	97,335	94,987
Total Assets	1,917,065	5,632,419
Accounts Payable	648,061	650,413
Accrued Expenses	820,114	864,295
Deferred Revenue	5,000	5,000
Total Current Liabilities	1,473,175	1,519,708
Accrued Expenses	432,376
Total Liabilities	1,905,551	1,519,708
Commitments and Contingencies
Common Stock, $.01 par value, 4,000,000 authorized, 208,259 and 123,711 outstanding	34,048	2,080
Additional paid-in capital	46,257,774	44,584,118
Accumulated deficit	(46,285,679)	(40,492,437)
Accumulated Other Comprehensive Income	4,579
Total Stockholders' Equity	11,514	4,112,711
Total Liabilities and Stockholders' Equity (Deficit)	$ 1,917,065	$ 5,632,419

Condensed Balance Sheets (Curr9

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2016	Sep. 16, 2016	Dec. 31, 2015	Jul. 24, 2015	Dec. 31, 2014	Nov. 30, 2014	Jun. 30, 2014
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000		20,000,000		10,000,000
Preferred stock, shares outstanding (in shares)	79,246		1,895,010		0
Preferred stock, par value (in dollars per share)							$ 487.50
Preferred stock, shares authorized (in shares)				20,000,000
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01		$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000	8,000,000	8,000,000	4,000,000	4,000,000
Common stock, shares outstanding (in shares)	3,404,860		208,259		123,711

Condensed Statements of Operati

Condensed Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 134,605	$ 85,792	$ 316,931	$ 471,078	$ 654,354	$ 951,559
Cost of goods sold	26,481	19,773	149,130	199,307	303,982	385,323
Gross Margin	108,124	66,019	167,801	271,771	350,372	566,236
General and administrative expense	733,074	861,098	4,684,130	1,589,522	3,399,339	4,882,549
Operations expense	292,856	202,799	928,062	375,429	846,687	972,830
Sales and marketing expense	137,784	66,720	348,848	439,703	503,989	1,178,305
Interest expense	3	51,804	3	394,641	390,887	377,719
Total expense	1,163,717	1,182,421	5,961,043	2,799,295	5,140,902	7,399,804
Net loss available to common shareholders	(1,055,593)	(1,116,402)	(5,793,242)	(2,527,524)	$ (4,790,530)	$ (6,833,568)
Unrealized gain (loss) from marketable securities	(1,299)		4,579
Comprehensive loss	$ (1,056,892)	$ (1,116,402)	$ (5,788,663)	$ (2,527,524)
Loss per common share - basic and diluted (in dollars per share)	$ (0.32)	$ (7.09)	$ (2.57)	$ (18.39)	$ (30.86)	$ (57.13)
Weighted average shares used in computation - basic and diluted (in shares)	3,320,139	157,445	2,250,315	137,428	155,233	119,619

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member]Stock Conversion 1 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 1 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Retained Earnings [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Retained Earnings [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]	Note Conversion 1 [Member]Common Stock [Member]	Note Conversion 1 [Member]Additional Paid-in Capital [Member]	Note Conversion 1 [Member]	Note Conversion 2 [Member]Common Stock [Member]	Note Conversion 2 [Member]Additional Paid-in Capital [Member]	Note Conversion 2 [Member]	Note Conversion 3 [Member]Common Stock [Member]	Note Conversion 3 [Member]Additional Paid-in Capital [Member]	Note Conversion 3 [Member]	Note Conversion 4 [Member]Common Stock [Member]	Note Conversion 4 [Member]Additional Paid-in Capital [Member]	Note Conversion 4 [Member]	Note Conversion 5 [Member]Common Stock [Member]	Note Conversion 5 [Member]Additional Paid-in Capital [Member]	Note Conversion 5 [Member]	Note Conversion 6 [Member]Common Stock [Member]	Note Conversion 6 [Member]Additional Paid-in Capital [Member]	Note Conversion 6 [Member]	Note Conversion 7 [Member]Common Stock [Member]	Note Conversion 7 [Member]Additional Paid-in Capital [Member]	Note Conversion 7 [Member]	Note Conversion 8 [Member]Common Stock [Member]	Note Conversion 8 [Member]Additional Paid-in Capital [Member]	Note Conversion 8 [Member]	Note Conversion 9 [Member]Common Stock [Member]	Note Conversion 9 [Member]Additional Paid-in Capital [Member]	Note Conversion 9 [Member]	Note Conversion 10 [Member]Common Stock [Member]	Note Conversion 10 [Member]Additional Paid-in Capital [Member]	Note Conversion 10 [Member]	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member]Common Stock [Member]	Investment Banker [Member]Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Former CEO [Member]Common Stock [Member]	Former CEO [Member]Additional Paid-in Capital [Member]	Former CEO [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2013																																																						$ 1,173	$ 25,477,788	$ (28,697,415)		$ (3,218,454)
Balance (in shares) at Dec. 31, 2013																																																						117,300
Reduction in escrow account per settlement agreement (in shares)																																																						178
Reduction in escrow account per settlement agreement																																																						$ (2)	(3,331)			(3,333)
Vesting Expense																																																							705,434			705,434
Shares issued in public offering; net																																																					206		2,054,795			2,055,001
Net loss																																																								(6,833,568)		(6,833,568)
Balance at Dec. 31, 2014																																																					206	$ 1,237	30,123,435	(35,641,105)		(5,516,227)
Balance (in shares) at Dec. 31, 2014																																																						123,711
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share (in shares)	125		125				125
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $243.75 per share	$ 1	$ (1)	$ 1	$ 30,399	$ (30,401)	$ (1)	$ 1	$ 30,401	$ (30,401)	$ 1
Reduction in escrow account per settlement agreement (in shares)																																																						(356)
Reduction in escrow account per settlement agreement																																																						$ (4)	(6,663)			(6,667)
Shares issued for a note conversion (in shares)											138			270			413			484			622			1,400			3,520			595			520			646
Shares issued for a note conversion											$ 1	$ 9,999	$ 10,000	$ 3	$ 19,997	$ 20,000	$ 4	$ 29,996	$ 30,000	$ 5	$ 33,473	$ 33,478	$ 6	$ 34,994	$ 35,000	$ 14	$ 69,986	$ 70,000	$ 35	$ 199,965	$ 200,000	$ 6	$ 29,994	$ 30,000	$ 5	$ 24,995	$ 25,000	$ 6	$ 29,994	$ 30,000
Vesting Expense																																																							871,877			871,877
Shares issued in public offering; net																																																					16,667	$ 667	13,043,546			13,060,880
Shares issued in public offering; net (in shares)																																																						66,667
Preferred stock conversion																																																					2,077	$ 91	(2,168)			0
Preferred stock conversion (in shares)																																																						9,134
Series A warrant exercise (in shares)																																																						120
Series A warrant exercise																																																						$ 1	9,899			9,900
Net loss																																																								(4,790,530)		(4,790,530)
Balance at Dec. 31, 2015																																																					18,950	$ 2,080	44,584,118	(40,492,437)		4,112,711
Balance (in shares) at Dec. 31, 2015																																																						208,259
Stock Issued During Period Shares Warrants Exercised																																																						120
Shares issued for cashless Series B warrant exercises per the tender offer exchange																																																						$ 1	9,899			9,900
Vesting Expense																																																							147,158			147,158
Shares issued in public offering; net																																															$ 260	$ 116,740	$ 117,000	$ 200	$ 90,151	$ 90,351
Shares issued in public offering; net (in shares)																																															26,000			20,000
Preferred stock conversion																																																					(18,158)	$ 664	17,494
Preferred stock conversion (in shares)																																																						66,396
Series A warrant exercise (in shares)																																									628,237													2,318,663
Series A warrant exercise																																									$ 6,282	$ 150,777	$ 157,059											$ 23,187	556,479			579,666
Net loss																																																								(5,793,242)		(5,793,242)
Balance at Sep. 30, 2016																																																					$ 792	$ 34,048	46,257,774	$ (46,285,679)	$ 4,579	11,514
Balance (in shares) at Sep. 30, 2016																																																						3,404,860
Shares issued for two options exercised at $65.75 per share (in shares)																																																						1,312
Shares issued for two options exercised at $65.75 per share																																																						$ 13	86,240			86,253
Stock Issued During Period Shares Warrants Exercised																																									628,237													2,318,663
Shares issued for cashless Series B warrant exercises per the tender offer exchange																																									$ 6,282	$ 150,777	$ 157,059											$ 23,187	556,479			579,666
Shares Issued (in shares)																																												135,995
Shares Issued																																												$ 1,360	$ 508,620	$ 509,980
Unrealized gain from marketable securities																																																									$ 4,579	$ 4,579
Corrections due to rounding for reverse split (in shares)																																																						(2)
Corrections due to rounding for reverse split																																																						$ 2	$ (3)

Statement of Stockholders' Eq12

Statement of Stockholders' Equity (Unaudited) (Parentheticals)	12 Months Ended
	Dec. 31, 2015$ / shares
Series A Convertible Preferred Stock [Member] | Stock Conversion 1 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Series A Convertible Preferred Stock [Member] | Stock Conversion 2 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Series A Convertible Preferred Stock [Member] | Stock Conversion 3 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Note Conversion 1 [Member]
Note conversion price (in dollars per share)	72.50
Note Conversion 2 [Member]
Note conversion price (in dollars per share)	74
Note Conversion 3 [Member]
Note conversion price (in dollars per share)	72.75
Note Conversion 4 [Member]
Note conversion price (in dollars per share)	69.25
Note Conversion 5 [Member]
Note conversion price (in dollars per share)	56.25
Note Conversion 6 [Member]
Note conversion price (in dollars per share)	50
Note Conversion 7 [Member]
Note conversion price (in dollars per share)	56.82
Note Conversion 8 [Member]
Note conversion price (in dollars per share)	50.45
Note Conversion 9 [Member]
Note conversion price (in dollars per share)	48.10
Note Conversion 10 [Member]
Note conversion price (in dollars per share)	$ 46.45

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities:
Net loss	$ (5,793,242)	$ (2,527,524)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	62,427	57,512
Vested stock options and warrants	147,158	320,334
Equity instruments issued for management and consulting	717,331	(6,667)
Issuance of common stock in cashless warrant exchange	736,724
Amortization of debt discount		219,097
Penalty on debt provision		10,031
Loss on Sales of Equipment	(2,387)	16,917
Gain from sale of marketable securities	(2,309)
Changes in assets and liabilities:
Accounts receivable	(6,734)	43,353
Inventories	(57,509)	130,477
Prepaid expense and other assets	108,391	(23,208)
Accounts payable	(2,352)	(1,056,006)
Accrued expenses	388,195	(1,845,850)
Deferred Revenue		24,180
Net cash used in operating activities:	(3,704,307)	(4,637,354)
Cash flow from investing activities:
Purchase of marketable securities	(850,000)
Proceeds from sale of marketable securities	280,000
Purchase of certificates of deposit	(1,000,000)
Redemption of certificates of deposit	1,000,000
Purchase of fixed assets	(25,127)
Purchase of intangibles	(8,573)	(23,739)
Net cash used in investing activities	(603,700)	(23,739)
Cash flow from financing activities:
Proceeds from long-term and convertible debt		250,000
Principal payments on debt		(933,074)
Issuance of preferred stock		18,950
Issuance of common stock	86,253	13,041,930
Net cash provided by financing activities	86,253	12,377,806
Net increase in cash and cash equivalents	(4,221,754)	7,716,713
Cash and cash equivalents at beginning of period	4,856,232	16,384
Cash and cash equivalents at end of period	634,478	7,733,097
Non cash transactions:
Common stock issued for accrued interest/bonus
Common stock issued to satisfy debt		$ 483,478

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations On October 27, 2016, the Company effected a 1-for-25 reverse stock split of its common stock. All share information in the financial statements for fiscal years 2016 and 2015 reflect the impact of the reverse stock split. Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of September 30, 2016, the registrant had 3,404,860 shares of common stock, par value $.01 per share, outstanding. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY® FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to September 30, 2016, the Company raised approximately $22,325,091 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.” Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. Debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts, rather than as an asset. Amortization of these costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual and interim reporting periods beginning after December 15, 2015. Early adoption is permitted. The adoption of this ASU is not expected to have an impact on our financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. We are currently evaluating the impact this guidance may have on our financial statements. In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” providing guidance on the balance sheet classification of deferred taxes. The guidance requires that deferred tax assets and liabilities to be classified as noncurrent in the Balance Sheet. The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842 In March 2016, the FASB issued ASU No. 2016-09, “ Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accountin During August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $10,343 and $57,004 in the three and nine months ended September 30, 2016 and were $500 and $1,917 in the three and nine months ended September 30, 2015. Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $79,936 and $302,330 in the three and nine months ended September 30, 2016 and were $58,792 and $179,739 in the three and nine months ended September 30, 2015. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of filters and fluids. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution or filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value. Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one year but greater than three months when purchased. Certificates with maturity dates beyond one year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value. Investment Securities Readily marketable investments in debt and equity securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions. The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 inputs. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: September 30, December 31, Finished goods $ 72,540 $ 30,237 Raw materials 157,044 162,623 Work-In-Process 59,665 38,880 Total $ 289,249 $ 231,740 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: September 30, December 31, Computers and office equipment $ 164,319 $ 153,553 Leasehold improvements 25,635 23,874 Manufacturing tooling 101,104 97,288 Demo Equipment 17,702 8,962 Total 308,760 283,677 Less: Accumulated depreciation 197,850 144,079 Total Fixed Assets, Net $ 110,910 $ 139,598 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $2,515 and $6,225 in the three and nine months ended September 30, 2016, and was $1,632 and $4,520 in the three and nine months ended September 30, 2015. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company has a credit risk concentration as a result of depositing $454,369 of funds in excess of insurance limits in a single bank. Product Warranty Costs In the three and nine months ending September 30, 2016 the incurred approximately $2,102 and $33,083 in current warranty costs and incurred $12,084 and $39,688 in warranty costs for the three and nine months ending September 30, 2015. Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues and expenses for the three and nine months ending September 30, 2016 and for 2015 in entirety were located at or derived from operations in the United States. There were no revenue from sales outside of the United States. The Company has recently attained its ISO 13485 certification and is applying to sell our products in Canada. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies. Subsequent Events The Company filed a Certificate of Amendment effecting a 1:25 reverse stock split (the “Reverse Stock Split” with the Secretary of State of the State of Delaware, which became effective under Delaware law at 5:00 p.m. New York time on October 27, 2016. The Company’s common stock opened for trading on October 28, 2016 on a post-split basis. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-25 basis such that every twenty-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. The share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination. Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 16, 2016. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of December 31, 2015, the registrant had 208,259 shares of common stock, par value $.01 per share, outstanding, adjusted for a 1-for-75 reverse stock split effective October 24, 2014, and then a 1-for-25 reverse stock split effective October 27, 2016. In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the both reverse stock splits. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to December 31, 2015, the Company raised approximately $22,732,961 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.” Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11 , Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2015 December 31, 2014 Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank. Product Warranty Costs In 2015, the Company incurred approximately $56,201 in current warranty costs. Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for 2015 and 2014 were located at or derived from operations in the United States. There were no revenues from sales outside of the United States. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Development Stage Oper

Note 2 - Development Stage Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception to October 24, 2016, 3,804,860 shares of common stock have been issued between par value and $3,131.25 (as adjusted for the reverse stock split). Operations since incorporation have been devoted to raising capital, obtaining financing, development of the Company’s product, and administrative services, customer acceptance and sales and marketing strategies.	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception through December 31, 2015, 208,259 shares of common stock have been issued between par value and $3,131.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies.

Note 3 - Stockholders' Equity (

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3 – STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. Public Offering of Units On August 31, 2015 (the “Issuance Date”), the Company completed a public offering (the “Offering”) of 1,666,667 Units (the “Units”) as described below. The public offering price in the Offering was $9.00 per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was $8.28 per Unit, resulting in an underwriting discount and commission of $0.72 (or 8.00%) per Unit and total net proceeds to the Company before expenses of $13.8 million. The Company had granted the Underwriter an option for a period of 45 days to purchase up to an additional 250,000 Units solely to cover over-allotments. The Underwriter chose not to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to $70,000. On August 31, 2015, as a result of the consummation of the Offering and the issuance of the 228,343 Exchange Units in the Unit Exchange described below, the Company issued a total of 1,895,010 Units, comprised of a total of aggregate of 75,800 shares of Common Stock (as adjusted for the reverse stock split), 1,895,010 shares of Series B Preferred Stock and 7,580,040 Series A Warrants, (as adjusted for the reverse stock split). Each Unit consisted of one share of common stock, par value $0.01 per share (the “Common Stock”), one share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and four Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants. Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black-Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered according to the following formula, referred to as the “Cashless Exercise.” Total Shares = (A x B)/C Where: · Total shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black-Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two trading days prior to the time of such exercise, provided that in no event may “C” be less than $0.43 per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock). The Black-Scholes Value (as defined above) as of September 30, 2016 was $108.115, and the closing bid price of Common Stock as of September 30, 2016, was $4.125. Therefore, an exercise on that date would have resulted in the issuance of 0.40 shares of Common Stock for each Series A Warrant. Approximately 6,141,115 Series A Warrants have been exercised in cashless exercises as of September 30, 2016, resulting in the issuance of 2,318,663 shares of Common Stock. If all of the remaining 35,084 Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on August 31, 2015 were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the two trading days prior to the time of such exercise was $123.75 per share or less and the Black-Scholes Value were $108.115 (the Black-Scholes Value as of September 30, 2016), then a total of an additional approximately 564 shares of our common stock would be issued to the holders of such Series A Warrants. The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company, determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three year anniversary of the Issuance Date, (1) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (2) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Unit Purchase Option. Series B Preferred Stock. Unit Exchange. Redemption of Convertible Notes. Registered Exchange Offer for Warrants. Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ("ASC 718"). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 174 shares of common stock to the former CEO at $31.25 per share upon his exercising options. In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 618 shares of common stock. In January and February 2014 the Company issued warrants to purchase 862 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $609.50. In February 2014 the Company issued a warrant to purchase 60 shares of common stock at an exercise price of $506.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 39 shares of common stock were issued to 16 holders of Preferred Shares. In March 2014, the Company issued 178 shares of common stock to a warrant holder for a partial cash exercise at $281.25 per share; issued 134 shares to the holder via the cashless exercise of the remainder of the warrant. In June 2014, the Company issued 149 shares of common stock to a warrant holder exercising cashless warrants. On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2014, the Company issued a warrant to purchase 218 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 194 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC in consideration for a bridge loan. In July 2014, the Company issued warrants to purchase 1,160 shares of common stock at an exercise price of $309.50 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. In August 2014, the Company issued warrants to purchase 2,462 of common stock at an exercise price of $609.50 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. In August and September 2014, the Company issued warrants to purchase 1,498 shares of common stock at an exercise price of $309.50 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. In November 2014, the Company issued 548 shares of common stock, par value $0.01, in escrow for debt settlement. On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $80.015 to $347.9864 per share. In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $487.50 per share, but should have been calculated at $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2015 the Company used a 1.63% to 2.35% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $6.8745 to $139.2386 per share. On March 25, 2016, the Company commenced the Exchange Offer which was completed on April 20, 2016, as described above. On July 1, 2016, the Company issued inducement stock options in accordance with NASDAQ listing rules for 40,000 shares of common stock, par value $0.01, at $3.75 per share to the Company’s newly hired Vice President of Sales. The options will vest in six equal increments: on the first, second, third, fourth, fifth and sixth quarters of the hiring date anniversary. On October 4, 2016, the Company issued 400,000 shares of common stock, par value $0.01, to be held in escrow in connection with the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC. For grants of stock options and warrants in 2016 the Company used a 1.46% to 1.78% risk free interest rate, 0% dividend rate, 66% volatility and estimated terms of 10 years. Value computed using these assumptions ranged from $1.6329 to $3.7195 per share. The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 100,837 3.329 730,882 1.44 Expired (22,377 ) 122.132 - - Exercised (1,312 ) 65.750 (939,879 ) - Outstanding at September 30, 2016 108,498 $ 15.652 114,102 $ 369.06 At September 30, 2016, 64,542 stock options are fully vested and currently exercisable with a weighted average exercise price of $23.46 and a weighted average remaining term of 9.57 years. All warrants are fully vested and exercisable. Stock-based compensation recognized for the nine months ending September 2016 and September 2015 was $1,393,862 and $320,334, respectively. The Company has $132,675 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over a period of approximately 18 months. The following summarizes the status of options and warrants outstanding at September 30, 2016: Range of Prices Shares Weighted Remaining Life Options $ 2.25 293 9.90 $ 2.42 37,152 9.89 $ 3.75 44,000 9.76 $ 4.125 3,636 10.00 $ 4.1975 7,147 9.97 $ 4.25 3,529 9.50 $ 5.125 3,902 9.94 $ 65.75 342 9.06 $ 73.50 1,157 9.26 $ 77.50 2,323 8.75 $ 80.25 187 9.01 $ 86.25 232 8.50 $ 121.875 5 6.45 $ 131.25 81 5.94 $ 148.125 928 6.47 $ 150.00 1,760 5.88 $ 162.50 123 8.26 $ 206.25 121 8.01 $ 248.4375 121 6.79 $ 262.50 130 6.79 $ 281.25 529 6.30 $ 318.75 3 6.60 $ 346.875 72 7.50 $ 431.25 306 7.44 $ 468.75 133 7.40 $ 506.25 188 7.25 $ 543.75 53 7.02 $ 596.25 42 7.00 108,498 Warrants $ 93.75 2,255 1.45 $ 123.75 94,084 3.92 $ 150.00 4,114 1.45 $ 225.00 107 1.32 $ 243.75 2,529 2.84 $ 281.25 5,897 1.20 $ 309.375 2,850 2.86 $ 309.50 222 3.10 $ 337.50 178 1.72 $ 371.25 944 1.66 $ 506.25 59 2.38 $ 609.375 862 2.34 114,102 Stock options and warrants expire on various dates from June 2017 to September 2026. On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 4,000,000 shares of common stock and the authorized preferred stock was increased to 20,000,000 shares. Under a Separation Agreement effective June 13, 2016, all of our former CEO Josh Kornberg’s 22,085 outstanding stock options were canceled. On September 16, 2016, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 8,000,000 shares of common stock. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of September 30, 2016 by year of grant: Stock Options: Year Shares Price 2011 173 0.00 - 281.25 2012 1,841 131.25 - 150.00 2013 1,612 121.88 - 596.25 2014 969 162.50 - 468.75 2015 4,240 65.75 - 86.25 2016 99,661 2.25 - 5.13 Total 108,498 $0.00 - 596.25 Warrants: Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 - 609.38 2015 94,152 0.00 - 243.75 Total 114,102 $0.00 - 609.38	NOTE 3 – STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS Public Offering of Units On August 31, 2015 (the “Issuance Date”), the Company completed a public offering (the “Offering”) of 1,666,667 Units (the “Units”) as described below. The public offering price in the Offering was $9.00 per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was $8.28 per Unit, resulting in an underwriting discount and commission of $0.72 (or 8.00%) per Unit and total net proceeds to the Company before expenses of $13.8 million. The Company had granted the Underwriter an option for a period of 45 days to purchase up to an additional 250,000 Units solely to cover over-allotments. The Underwriter chose not to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to $70,000. On August 31, 2015, as a result of the communication of the Offering and the issuance of the 228,343 Exchange Units in the Unit Exchange described below, the Company issued a total of 1,895,010 Units, comprised of a total of aggregate of 75,800 shares of Common Stock, 1,895,010 shares of Series B Preferred Stock and 7,580,040 Series A Warrants. Each Unit consisted of one share of common stock, par value $0.01 per share (the “Common Stock”), one share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and four Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered will be determined according to the following formula, referred to as the “Cashless Exercise.” Total Shares = (A x B) / C Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two trading days prior to the time of such exercise, provided that in no event may “C” be less than $10.75 per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock). The Black Scholes Value (as defined above) as of March 11, 2016 was $108.115, and the closing bid price of Common Stock as of March 11, 2016, was $4.50. Therefore, an exercise on that date would have resulted in the issuance of 0.40 shares of Common Stock for each Series A Warrant. Approximately 3,390,935 Series A Warrants have been exercised in cashless exercises as of March 11, 2016, resulting in the issuance of 1,362,147 shares of Common Stock. If all of the remaining 4,189,105 Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on August 31, 2015 were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the two trading days prior to the time of such exercise was $10.75 per share or less and the Black Scholes Value were $4.3246 (the Black Scholes Value as of March 11, 2016), then a total of approximately 1,685,229 shares of our common stock would be issued to the holders of such Series A Warrants. The potential for such dilutive exercise of the Series A Warrants may depress the price of our common stock regardless of the Company’s business performance, and could encourage short selling by market participants, especially if the trading price of our common stock begins to decrease. The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company, determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three year anniversary of the Issuance Date, (1) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (2) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Unit Purchase Option. Series B Preferred Stock. Unit Exchange. Redemption of Convertible Notes. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 174 shares of common stock to the former CEO at $31.25 per share upon his exercising options. In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 618 shares of common stock. In January and February 2014 the Company issued warrants to purchase 862 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $609.50. In February 2014 the Company issued a warrant to purchase 60 shares of common stock at an exercise price of $506.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 39 shares of common stock were issued to 16 holders of Preferred Shares. In March 2014, the Company issued 178 shares of common stock to a warrant holder for a partial cash exercise at $281.25 per share; issued 134 shares to the holder via the cashless exercise of the remainder of the warrant. In June 2014, the Company issued 149 shares of common stock to a warrant holder exercising cashless warrants. On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2014, the Company issued a warrant to purchase 218 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 194 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC in consideration for a bridge loan. In July 2014, the Company issued warrants to purchase 1,160 shares of common stock at an exercise price of $309.50 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. In August 2014, the Company issued warrants to purchase 2,462 of common stock at an exercise price of $609.50 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. In August and September 2014, the Company issued warrants to purchase 1,498 shares of common stock at an exercise price of $309.50 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. In November 2014, the Company issued 548 shares of common stock, par value $0.01, in escrow for debt settlement. On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $80.02 to $347.99 per share. In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $487.50 per share, but should have been calculated at $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2015 the Company used a 1.63% to 2.35% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $6.88 to $139.24 per share. The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2013 15,430 $ 168.75 18,477 $ 262.50 Issued 3,028 203.00 6,455 95.25 Expired (316 ) 589.50 (3,275 ) 338.50 Exercised (198 ) 44.00 (1,629 ) 209.50 Outstanding at December 31, 2014 17,944 $ 187.75 20,028 $ 198.75 Issued 14,171 69.00 303,269 123.75 Cancelled (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,349 $ 133.25 323,098 $ 128.50 At December 31, 2015, 31,229 stock options are fully vested and currently exercisable with a weighted average exercise price of $132.25 and a weighted average remaining term of 8.17 years. There are 323,098 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2015 and 2014 was $871,877 and $723,367, respectively. The Company has $32,682 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 2 months. The following summarizes the status of options and warrants outstanding at December 31, 2015: Range of Exercise Prices Shares Weighted Options: $18.75 293 5.52 $65.75 10,019 9.81 $73.50 1,225 10.01 $77.50 2,387 9.50 $80.25 250 9.76 $86.25 289 9.25 $121.88 6 7.20 $131.25 82 6.69 $140.63 7,679 7.21 $148.13 929 7.22 $150.00 4,959 6.63 $162.50 153 9.01 $206.25 145 8.76 $248.44 120 7.54 $262.50 130 7.54 $281.25 546 7.09 $318.75 3 7.36 $346.88 87 8.25 $431.25 1,610 8.19 $468.75 134 8.15 $506.25 198 8.01 $543.75 54 7.77 $596.25 51 7.75 Total 31,349 Warrants: $123.75 303,081 4.67 $150.00 4,114 2.20 $225.00 107 2.07 $243.75 2,529 3.59 $281.25 8,152 2.02 $309.38 2,850 3.61 $309.50 222 3.85 $337.50 178 2.47 $371.25 944 2.41 $506.25 59 3.13 $609.38 861 3.10 Total 323,098 Stock options and warrants expire on various dates from June 2017 to December 2025. On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 4,000,000 shares of common stock and the authorized preferred stock was increased to 20,000,000 shares. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2015 by year of grant: Stock Options: Year Shares Price 2011 467 18.75 2012 5,041 131.25 – 150.00 2013 9,310 121.88 – 596.25 2014 2,361 162.50 – 468.75 2015 14,170 65.75 – 86.25 Total 31,349 $ 18.75 – 596.25 Warrants: Year Shares Price 2012 2,792 281.25 – 375.00 2013 10,703 150.00 – 371.25 2014 6,455 309.38 – 609.38 2015 303,148 123.75 Total 323,098 $ 123.75 – 609.38

Note 4 - Short-term Notes Payab

Note 4 - Short-term Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $1.8 million original principal amount (subsequently reduced to approximately $1.6 million aggregate principal amount in accordance with their terms) of convertible promissory notes (the “2014 Convertible Notes”) and warrants exercisable for shares of our common stock for an aggregate purchase price of $1,475,000. Of this amount, we issued to SOK Partners, LLC, an affiliate of the Company, $122,196 original principal amount of the 2014 Convertible Notes and warrants exercisable for 218 shares of our common stock for an aggregate purchase price of $100,000. In April and May 2015, we issued and sold to a private investor additional Convertible Notes in an aggregate original principal amount of $275,000 for an aggregate purchase price of $250,000, containing terms substantially similar to the 2014 Convertible Notes (the “2015 Convertible Notes” and, together with the 2014 Convertible Notes, the “Convertible Notes”). No warrants were issued with the 2015 Convertible Notes. Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11%, to $1,603,260 and the number of Warrants was reduced by 11%, to 2,851 shares. As of September 30, 2016 $927,663 aggregate principal amount of Convertible Notes, plus accrued and unpaid interest thereto, have been converted into shares of our common stock and no aggregate principal amount of Convertible Notes remains outstanding. In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% of the principal amount, plus accrued and unpaid interest to the redemption date. On August 31, 2015, the closing date of the offering, the Company redeemed the remaining $933,074 aggregate principal amount of Convertible Notes plus interest and a 40% redeemable premium, for a total payment of $1,548,792. Of this amount, approximately $167,031 was paid to its affiliates in redemption of their Convertible Notes. Each holder of the Convertible Notes agreed to the foregoing terms and entered into an Amendment to Senior Convertible Notes and Agreement with the Company. As of September 30, 2016, none of the Convertible Notes were outstanding.	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $1.8 million original principal amount (subsequently reduced to approximately $1.6 million aggregate principal amount in accordance with their terms) of convertible promissory notes (the “2014 Convertible Notes”) and warrants exercisable for shares of our common stock for an aggregate purchase price of $1,475,000. Of this amount, we issued to SOK Partners, LLC, an affiliate of the Company, $122,196 original principal amount of the 2014 Convertible Notes and warrants exercisable for 218 shares of our common stock for an aggregate purchase price of $100,000. In April and May 2015, we issued and sold to a private investor additional Convertible Notes in an aggregate original principal amount of $275,000 for an aggregate purchase price of $250,000, containing terms substantially similar to the 2014 Convertible Notes (the “2015 Convertible Notes” and, together with the 2014 Convertible Notes, the “Convertible Notes”). No warrants were issued with the 2015 Convertible Notes. Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11%, to $1,603,260 and the number of Warrants was reduced by 11%, to 2,851 shares. As of June 30, 2015, $927,663 aggregate principal amount of Convertible Notes, plus accrued and unpaid interest thereto, have been converted into shares of our common stock and $933,073 aggregate principal amount of Convertible Notes remained outstanding. In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% of the principal amount, plus accrued and unpaid interest to the redemption date. On August 31, 2015, the closing date of the offering, the Company redeemed the remaining $933,074 aggregate principal amount of Convertible Notes plus interest and a 40% redeemable premium, for a total payment of $1,548,792. Of this amount, approximately $167,031 was paid to its affiliates in redemption of their Convertible Notes. Each holder of the Convertible Notes agreed to the foregoing terms and entered into an Amendment to Senior Convertible Notes and Agreement with the Company. As of December 31, 2015 none of the Convertible Notes were outstanding.

Note 5 - Loss Per Share

Note 5 - Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (1,055,593 ) $ (1,116,402 ) $ (5,793,242 ) $ (2,527,524 ) Other comprehensive income: Unrealized gain (loss) from marketable securities (1,299 ) - 4,579 - Comprehensive (loss) (1,056,892 ) (1,116,402 ) (5,788,663 ) (2,527,524 ) Denominator: Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Loss per common share-basic and diluted $ (0.32 ) $ (7.09 ) $ (2.57 ) $ (18.39 ) (1) The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 155,234 119,619 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 155,234 119,619 Loss per common share-basic and diluted $ (30.86 ) $ (57.13 ) (1) The number of shares underlying options and warrants outstanding as of December 31, 2015 and December 31, 2014 are 354.447 and 37,972, respectively. The number of shares underlying the preferred stock as of December 31, 2015 is 75,921. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes

Note 6 - Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6 – INCOME TAXES Availability and Utilization of Net Operating Losses During September 2013, the Company experienced an “ownership change” as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. During the first quarter of 2016, the Company likely had another ownership change that could further limit the Company’s ability to fully utilize its NOLs however, the determination of the annual limitation has not yet been made. Income Taxes At December 31, 2015, the Company had approximately $24.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2016, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $13.4 million of gross NOLs to reduce future state taxable income at December 31, 2015, which will expire in years 2022 through 2036 if unused. The Company’s net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2015, the federal and state valuation allowances were $9.6 million and $1.1 million, respectively. At September 30, 2016, the Company had approximately $29.2 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2017, subject to the Section 382 limitations described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $15.0 million of gross NOLs to reduce future state taxable income at September 30, 2016, which will expire in years 2022 through 2037 if unused. The Company’s net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At September 30, 2016, the federal and state valuation allowances were $10.1 million and $0.3 million, respectively. The components of deferred income taxes at September 30, 2016 and December 31, 2015 are as follows: September 30, December 31, Deferred Tax Asset: Net Operating Loss $ 10,271,000 $ 10,338,000 Other 166,000 359,000 Total Deferred Tax Asset 10,437,000 10,697,000 Less Valuation Allowance 10,437,000 10,697,000 Net Deferred Income Taxes $ — $ —	NOTE 6– INCOME TAXES The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate. During September 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. At December 31, 2014, the Company had approximately $18.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $12.4 million of gross NOLs to reduce future state taxable income at December 31, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2014, the federal and state valuation allowances were $8.1 million and $1.0 million, respectively. At December 31, 2015, the Company had approximately $24.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2016, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $13.4 million of gross NOLs to reduce future state taxable income at December 31, 2015, which will expire in years 2022 through 2035 if unused. The Company’s net deferred tax assets, which include the NOLs are subject to a full valuation allowance. At December 31, 2015, the federal and state valuation allowances were $9.6 million and $1.1 million, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2015 and December 31, 2014 are as follows: December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation

Note 7 - Rent Obligation	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $16,356 and $50,106 for the three and nine months ended September 30, 2016 and was $15,900 and $50,156 for the three and nine months ended September 30, 2015 respectively. The Company’s rent obligation for the next three years is as follows: 2016 $ 9,500 2017 $ 39,000 2018 $ 3,600	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $66,345 and $64,753 for 2015 and 2014, respectively. The Company’s rent obligation for the next three years are as follows: 2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 8 - Liability for Equity-l

Note 8 - Liability for Equity-linked Financial Instruments	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 8 – LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability. The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $862.50 per share, a stock price of $656.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black- Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $937.50 to $412.50 per share in the underlying stock price. The Company realized a slight increase in the liability for existing warrants during the first quarter of 2012. In 2013 there was a significant decrease in the liability primarily due to current expirations and the amount of warrants reaching expiration in the near term. In 2014, all warrants expired and the liability was reduced to zero. The inputs to the Black-Scholes model during 2009 through 2014 were as follows: Stock price $93.75 to $937.50 Exercise price $18.75 to $609.50 Expected life (years) 2.0 to 6.5 Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13% to 2.97% The original valuations, annual gain (loss) and end of year valuations are shown below: Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 2012 Gain Value 2013 Gain Value 2014 Gain Value at January 1, 2009 adoption $ 479,910 $ (390,368 ) $ 870,278 $ 868,772 $ 1,506 $ (88,290 ) $ 89,796 $ (21,856 ) $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 6/30/2009 169,854 20,847 149,007 147,403 1,604 (4,689 ) 6,293 6,293 - - - - - Warrants issued in quarter ended 9/30/2009 39,743 (738 ) 40,481 40,419 62 (1,562 ) 1,624 910 714 714 - - - Warrants is used in quarter ended 12/31/2009 12,698 617 12,081 12,053 28 (724 ) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 3/31/2010 25,553 25,014 539 (5,570 ) 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 6/30/2010 31,332 30,740 592 (6,122 ) 6,714 6,083 631 631 - - - Warrants issued in quarter ended 9/30/2010 31,506 20,891 10,615 (44,160 ) 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 ) $ 1,071,847 $ 1,145,292 $ 14,946 $ (151,117 ) $ 166,063 $ (3,116 ) $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

Note 9 - Related Party Transcat

Note 9 - Related Party Transcations	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In connection with the sale of the Series A Preferred Share on February 4, 2014, Josh Kornberg, our former, and then President, CEO and Interim Chairman of the Board, was one of the Purchasers. Mr. Kornberg purchased 770 Preferred Shares for a purchase price of $25,000 and received warrants to purchase 3 shares of common stock. SOK Partners, LLC (“SOK”), a large stockholder with Mr. Kornberg and Dr. Samuel Herschkowitz as managing partners, invested in the July 2014 offering of convertible notes and warrants. In November 2014, the convertible noteholders agreed to convert certain balances of the convertible notes in connection with the public offering of the Existing Units, in consideration of the agreement to issue certain additional shares. See “Management’s Discussion and Analysis of Financial Conditions and Results of Operations – Liquidity and Capital Resources – History Financing – 2014 Sales of Convertible Notes and Warrants.” In connection with the Unit Offering in August 2015, all such convertible notes were redeemed at a redemption price of 140% of the principal amount thereof, plus accrued and unpaid interest. The Company paid approximately $163,000 to SOK in redemption of its convertible note. In addition, Rick Koenigsberger, a former director who resigned on June 5, 2015, is a holder of membership units of SOK Partners. In connection with the Unit Exchange that was consummated on August 31, 2015, 250 shares of Series A Convertible Stock held by Mr. Kornberg were exchanged for 2,778 Exchange Units.	NOTE 9 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners. In connection with the sale of the Series A Preferred Shares on February 4, 2014, Joshua Kornberg, our President, Chief Executive Officer and Interim Chairman of the Board, was one of the purchasers. Mr. Kornberg purchased 19,231 Series A Preferred Shares for a purchase price of $25,000 and received warrants to purchase 3 shares of common stock. SOK Partners, LLC (“SOK”), a 10% stockholder with Mr. Kornberg and Dr. Samuel Herschkowitz as managing partners, invested in the July 2014 offering of convertible notes and warrants. In November 2014, the convertible noteholders agreed to convert certain balances of the convertible notes in connection with the public offering of the Existing Units, in consideration of the agreement to issue certain additional shares. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – History Financing – 2014 Sales of Convertible Notes and Warrants.” In connection with the Unit Offering in August 2015, all such convertible notes were redeemed at a redemption price of 140% of the principal amount thereof, plus accrued and unpaid interest. The Company paid approximately $163,000 to SOK in redemption of its convertible note. In addition, Ricardo Koenigsberger, a former director who resigned on June 5, 2015, is a holder of membership units of SOK Partners. In connection with the Unit Exchange that was consummated on August 31, 2015, 250 shares of Series A Convertible Stock held by Mr. Kornberg were exchanged for 2,778 Exchange Units.

Note 10 - Retirement Savings Pl

Note 10 - Retirement Savings Plans	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 – RETIREMENT SAVINGS PLAN We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2016 and 2015, we matched 100%, of the employee’s contribution up to 4% of their earnings. The employer contribution was $7,401 and $28,196 for the three and nine months ending September 30, 2016 and was $7,021 and $21,735 for the three and nine months ending September 30, 2015, respectively.	NOTE 10 – RETIREMENT SAVINGS PLANS We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2014, and again in 2015, we matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $39,916 and $37,730 in 2015 and 2014. There were no discretionary contributions to the plan in 2015 and 2014.

Note 11 - Supplemental Cash Flo

Note 11 - Supplemental Cash Flow Data	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 10 – SUPPLEMENTAL CASH FLOW DATA There were $3 in cash payments for interest for the three and nine months ended September 30, 2016 and were $226,960 and $237,121 for the three and nine months ended September 30, 2015.	NOTE 11 – SUPPLEMENTAL CASH FLOW DATA Cash payments for interest were $246,620 and $47,111 for the fiscal years ended December 31, 2015 and December 31, 2014, respectively.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 12 – SUBSEQUENT EVENTS In January 2016 we commenced a registered offer (the “Exchange Offer”) to exchange, on a one-for-one basis, new units (the “New Units”) in exchange for the 1,895,010 outstanding units (the “Existing Units”) that were issued in the Offering and the Unit Exchange. Each New Unit, if issued, would have consisted of shares of common stock and certain warrants to purchase common stock. On March 2, 2016, we announced the termination of the Exchange Offer. None of the Existing Units were accepted for exchange in the Exchange Offer.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II Valuation and Qualifying Accounts (None)

Note 1 - Summary of Significa27

Note 1 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations On October 27, 2016, the Company effected a 1-for-25 reverse stock split of its common stock. All share information in the financial statements for fiscal years 2016 and 2015 reflect the impact of the reverse stock split. Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of September 30, 2016, the registrant had 3,404,860 shares of common stock, par value $.01 per share, outstanding. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY® FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to September 30, 2016, the Company raised approximately $22,325,091 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.” Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. Debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts, rather than as an asset. Amortization of these costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual and interim reporting periods beginning after December 15, 2015. Early adoption is permitted. The adoption of this ASU is not expected to have an impact on our financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. We are currently evaluating the impact this guidance may have on our financial statements. In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” providing guidance on the balance sheet classification of deferred taxes. The guidance requires that deferred tax assets and liabilities to be classified as noncurrent in the Balance Sheet. The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842 In March 2016, the FASB issued ASU No. 2016-09, “ Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accountin During August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $10,343 and $57,004 in the three and nine months ended September 30, 2016 and were $500 and $1,917 in the three and nine months ended September 30, 2015. Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $79,936 and $302,330 in the three and nine months ended September 30, 2016 and were $58,792 and $179,739 in the three and nine months ended September 30, 2015. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of filters and fluids. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution or filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value. Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one year but greater than three months when purchased. Certificates with maturity dates beyond one year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value. Investment Securities Readily marketable investments in debt and equity securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions. The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 inputs. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: September 30, December 31, Finished goods $ 72,540 $ 30,237 Raw materials 157,044 162,623 Work-In-Process 59,665 38,880 Total $ 289,249 $ 231,740 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: September 30, December 31, Computers and office equipment $ 164,319 $ 153,553 Leasehold improvements 25,635 23,874 Manufacturing tooling 101,104 97,288 Demo Equipment 17,702 8,962 Total 308,760 283,677 Less: Accumulated depreciation 197,850 144,079 Total Fixed Assets, Net $ 110,910 $ 139,598 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $2,515 and $6,225 in the three and nine months ended September 30, 2016, and was $1,632 and $4,520 in the three and nine months ended September 30, 2015. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company has a credit risk concentration as a result of depositing $454,369 of funds in excess of insurance limits in a single bank. Product Warranty Costs In the three and nine months ending September 30, 2016 the incurred approximately $2,102 and $33,083 in current warranty costs and incurred $12,084 and $39,688 in warranty costs for the three and nine months ending September 30, 2015. Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues and expenses for the three and nine months ending September 30, 2016 and for 2015 in entirety were located at or derived from operations in the United States. There were no revenue from sales outside of the United States. The Company has recently attained its ISO 13485 certification and is applying to sell our products in Canada. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies. Subsequent Events The Company filed a Certificate of Amendment effecting a 1:25 reverse stock split (the “Reverse Stock Split” with the Secretary of State of the State of Delaware, which became effective under Delaware law at 5:00 p.m. New York time on October 27, 2016. The Company’s common stock opened for trading on October 28, 2016 on a post-split basis. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-25 basis such that every twenty-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. The share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination. Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 16, 2016. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of December 31, 2015, the registrant had 208,259 shares of common stock, par value $.01 per share, outstanding, adjusted for a 1-for-75 reverse stock split effective October 24, 2014, and then a 1-for-25 reverse stock split effective October 27, 2016. In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the both reverse stock splits. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to December 31, 2015, the Company raised approximately $22,732,961 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.” Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11 , Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2015 December 31, 2014 Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank. Product Warranty Costs In 2015, the Company incurred approximately $56,201 in current warranty costs. Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for 2015 and 2014 were located at or derived from operations in the United States. There were no revenues from sales outside of the United States. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Development Stage Op28

Note 2 - Development Stage Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception to October 24, 2016, 3,804,860 shares of common stock have been issued between par value and $3,131.25 (as adjusted for the reverse stock split). Operations since incorporation have been devoted to raising capital, obtaining financing, development of the Company’s product, and administrative services, customer acceptance and sales and marketing strategies.	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception through December 31, 2015, 208,259 shares of common stock have been issued between par value and $3,131.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies.

Note 3 - Stockholders' Deficit,

Note 3 - Stockholders' Deficit, Stock Options and Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3 – STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. Public Offering of Units On August 31, 2015 (the “Issuance Date”), the Company completed a public offering (the “Offering”) of 1,666,667 Units (the “Units”) as described below. The public offering price in the Offering was $9.00 per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was $8.28 per Unit, resulting in an underwriting discount and commission of $0.72 (or 8.00%) per Unit and total net proceeds to the Company before expenses of $13.8 million. The Company had granted the Underwriter an option for a period of 45 days to purchase up to an additional 250,000 Units solely to cover over-allotments. The Underwriter chose not to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to $70,000. On August 31, 2015, as a result of the consummation of the Offering and the issuance of the 228,343 Exchange Units in the Unit Exchange described below, the Company issued a total of 1,895,010 Units, comprised of a total of aggregate of 75,800 shares of Common Stock (as adjusted for the reverse stock split), 1,895,010 shares of Series B Preferred Stock and 7,580,040 Series A Warrants, (as adjusted for the reverse stock split). Each Unit consisted of one share of common stock, par value $0.01 per share (the “Common Stock”), one share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and four Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants. Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black-Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered according to the following formula, referred to as the “Cashless Exercise.” Total Shares = (A x B)/C Where: · Total shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black-Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two trading days prior to the time of such exercise, provided that in no event may “C” be less than $0.43 per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock). The Black-Scholes Value (as defined above) as of September 30, 2016 was $108.115, and the closing bid price of Common Stock as of September 30, 2016, was $4.125. Therefore, an exercise on that date would have resulted in the issuance of 0.40 shares of Common Stock for each Series A Warrant. Approximately 6,141,115 Series A Warrants have been exercised in cashless exercises as of September 30, 2016, resulting in the issuance of 2,318,663 shares of Common Stock. If all of the remaining 35,084 Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on August 31, 2015 were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the two trading days prior to the time of such exercise was $123.75 per share or less and the Black-Scholes Value were $108.115 (the Black-Scholes Value as of September 30, 2016), then a total of an additional approximately 564 shares of our common stock would be issued to the holders of such Series A Warrants. The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company, determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three year anniversary of the Issuance Date, (1) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (2) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Unit Purchase Option. Series B Preferred Stock. Unit Exchange. Redemption of Convertible Notes. Registered Exchange Offer for Warrants. Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ("ASC 718"). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 174 shares of common stock to the former CEO at $31.25 per share upon his exercising options. In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 618 shares of common stock. In January and February 2014 the Company issued warrants to purchase 862 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $609.50. In February 2014 the Company issued a warrant to purchase 60 shares of common stock at an exercise price of $506.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 39 shares of common stock were issued to 16 holders of Preferred Shares. In March 2014, the Company issued 178 shares of common stock to a warrant holder for a partial cash exercise at $281.25 per share; issued 134 shares to the holder via the cashless exercise of the remainder of the warrant. In June 2014, the Company issued 149 shares of common stock to a warrant holder exercising cashless warrants. On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2014, the Company issued a warrant to purchase 218 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 194 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC in consideration for a bridge loan. In July 2014, the Company issued warrants to purchase 1,160 shares of common stock at an exercise price of $309.50 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. In August 2014, the Company issued warrants to purchase 2,462 of common stock at an exercise price of $609.50 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. In August and September 2014, the Company issued warrants to purchase 1,498 shares of common stock at an exercise price of $309.50 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. In November 2014, the Company issued 548 shares of common stock, par value $0.01, in escrow for debt settlement. On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $80.015 to $347.9864 per share. In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $487.50 per share, but should have been calculated at $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2015 the Company used a 1.63% to 2.35% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $6.8745 to $139.2386 per share. On March 25, 2016, the Company commenced the Exchange Offer which was completed on April 20, 2016, as described above. On July 1, 2016, the Company issued inducement stock options in accordance with NASDAQ listing rules for 40,000 shares of common stock, par value $0.01, at $3.75 per share to the Company’s newly hired Vice President of Sales. The options will vest in six equal increments: on the first, second, third, fourth, fifth and sixth quarters of the hiring date anniversary. On October 4, 2016, the Company issued 400,000 shares of common stock, par value $0.01, to be held in escrow in connection with the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC. For grants of stock options and warrants in 2016 the Company used a 1.46% to 1.78% risk free interest rate, 0% dividend rate, 66% volatility and estimated terms of 10 years. Value computed using these assumptions ranged from $1.6329 to $3.7195 per share. The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 100,837 3.329 730,882 1.44 Expired (22,377 ) 122.132 - - Exercised (1,312 ) 65.750 (939,879 ) - Outstanding at September 30, 2016 108,498 $ 15.652 114,102 $ 369.06 At September 30, 2016, 64,542 stock options are fully vested and currently exercisable with a weighted average exercise price of $23.46 and a weighted average remaining term of 9.57 years. All warrants are fully vested and exercisable. Stock-based compensation recognized for the nine months ending September 2016 and September 2015 was $1,393,862 and $320,334, respectively. The Company has $132,675 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over a period of approximately 18 months. The following summarizes the status of options and warrants outstanding at September 30, 2016: Range of Prices Shares Weighted Remaining Life Options $ 2.25 293 9.90 $ 2.42 37,152 9.89 $ 3.75 44,000 9.76 $ 4.125 3,636 10.00 $ 4.1975 7,147 9.97 $ 4.25 3,529 9.50 $ 5.125 3,902 9.94 $ 65.75 342 9.06 $ 73.50 1,157 9.26 $ 77.50 2,323 8.75 $ 80.25 187 9.01 $ 86.25 232 8.50 $ 121.875 5 6.45 $ 131.25 81 5.94 $ 148.125 928 6.47 $ 150.00 1,760 5.88 $ 162.50 123 8.26 $ 206.25 121 8.01 $ 248.4375 121 6.79 $ 262.50 130 6.79 $ 281.25 529 6.30 $ 318.75 3 6.60 $ 346.875 72 7.50 $ 431.25 306 7.44 $ 468.75 133 7.40 $ 506.25 188 7.25 $ 543.75 53 7.02 $ 596.25 42 7.00 108,498 Warrants $ 93.75 2,255 1.45 $ 123.75 94,084 3.92 $ 150.00 4,114 1.45 $ 225.00 107 1.32 $ 243.75 2,529 2.84 $ 281.25 5,897 1.20 $ 309.375 2,850 2.86 $ 309.50 222 3.10 $ 337.50 178 1.72 $ 371.25 944 1.66 $ 506.25 59 2.38 $ 609.375 862 2.34 114,102 Stock options and warrants expire on various dates from June 2017 to September 2026. On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 4,000,000 shares of common stock and the authorized preferred stock was increased to 20,000,000 shares. Under a Separation Agreement effective June 13, 2016, all of our former CEO Josh Kornberg’s 22,085 outstanding stock options were canceled. On September 16, 2016, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 8,000,000 shares of common stock. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of September 30, 2016 by year of grant: Stock Options: Year Shares Price 2011 173 0.00 - 281.25 2012 1,841 131.25 - 150.00 2013 1,612 121.88 - 596.25 2014 969 162.50 - 468.75 2015 4,240 65.75 - 86.25 2016 99,661 2.25 - 5.13 Total 108,498 $0.00 - 596.25 Warrants: Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 - 609.38 2015 94,152 0.00 - 243.75 Total 114,102 $0.00 - 609.38	NOTE 3 – STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS Public Offering of Units On August 31, 2015 (the “Issuance Date”), the Company completed a public offering (the “Offering”) of 1,666,667 Units (the “Units”) as described below. The public offering price in the Offering was $9.00 per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was $8.28 per Unit, resulting in an underwriting discount and commission of $0.72 (or 8.00%) per Unit and total net proceeds to the Company before expenses of $13.8 million. The Company had granted the Underwriter an option for a period of 45 days to purchase up to an additional 250,000 Units solely to cover over-allotments. The Underwriter chose not to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to $70,000. On August 31, 2015, as a result of the communication of the Offering and the issuance of the 228,343 Exchange Units in the Unit Exchange described below, the Company issued a total of 1,895,010 Units, comprised of a total of aggregate of 75,800 shares of Common Stock, 1,895,010 shares of Series B Preferred Stock and 7,580,040 Series A Warrants. Each Unit consisted of one share of common stock, par value $0.01 per share (the “Common Stock”), one share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and four Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered will be determined according to the following formula, referred to as the “Cashless Exercise.” Total Shares = (A x B) / C Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two trading days prior to the time of such exercise, provided that in no event may “C” be less than $10.75 per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock). The Black Scholes Value (as defined above) as of March 11, 2016 was $108.115, and the closing bid price of Common Stock as of March 11, 2016, was $4.50. Therefore, an exercise on that date would have resulted in the issuance of 0.40 shares of Common Stock for each Series A Warrant. Approximately 3,390,935 Series A Warrants have been exercised in cashless exercises as of March 11, 2016, resulting in the issuance of 1,362,147 shares of Common Stock. If all of the remaining 4,189,105 Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on August 31, 2015 were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the two trading days prior to the time of such exercise was $10.75 per share or less and the Black Scholes Value were $4.3246 (the Black Scholes Value as of March 11, 2016), then a total of approximately 1,685,229 shares of our common stock would be issued to the holders of such Series A Warrants. The potential for such dilutive exercise of the Series A Warrants may depress the price of our common stock regardless of the Company’s business performance, and could encourage short selling by market participants, especially if the trading price of our common stock begins to decrease. The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company, determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three year anniversary of the Issuance Date, (1) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (2) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Unit Purchase Option. Series B Preferred Stock. Unit Exchange. Redemption of Convertible Notes. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 174 shares of common stock to the former CEO at $31.25 per share upon his exercising options. In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 618 shares of common stock. In January and February 2014 the Company issued warrants to purchase 862 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $609.50. In February 2014 the Company issued a warrant to purchase 60 shares of common stock at an exercise price of $506.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 39 shares of common stock were issued to 16 holders of Preferred Shares. In March 2014, the Company issued 178 shares of common stock to a warrant holder for a partial cash exercise at $281.25 per share; issued 134 shares to the holder via the cashless exercise of the remainder of the warrant. In June 2014, the Company issued 149 shares of common stock to a warrant holder exercising cashless warrants. On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2014, the Company issued a warrant to purchase 218 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 194 shares of common stock at an exercise price of $309.50 to SOK Partners, LLC in consideration for a bridge loan. In July 2014, the Company issued warrants to purchase 1,160 shares of common stock at an exercise price of $309.50 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. In August 2014, the Company issued warrants to purchase 2,462 of common stock at an exercise price of $609.50 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. In August and September 2014, the Company issued warrants to purchase 1,498 shares of common stock at an exercise price of $309.50 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. In November 2014, the Company issued 548 shares of common stock, par value $0.01, in escrow for debt settlement. On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $487.50 per share. As a result 63 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $80.02 to $347.99 per share. In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $487.50 per share, but should have been calculated at $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $243.75 per share. As a result 125 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2015 the Company used a 1.63% to 2.35% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $6.88 to $139.24 per share. The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2013 15,430 $ 168.75 18,477 $ 262.50 Issued 3,028 203.00 6,455 95.25 Expired (316 ) 589.50 (3,275 ) 338.50 Exercised (198 ) 44.00 (1,629 ) 209.50 Outstanding at December 31, 2014 17,944 $ 187.75 20,028 $ 198.75 Issued 14,171 69.00 303,269 123.75 Cancelled (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,349 $ 133.25 323,098 $ 128.50 At December 31, 2015, 31,229 stock options are fully vested and currently exercisable with a weighted average exercise price of $132.25 and a weighted average remaining term of 8.17 years. There are 323,098 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2015 and 2014 was $871,877 and $723,367, respectively. The Company has $32,682 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 2 months. The following summarizes the status of options and warrants outstanding at December 31, 2015: Range of Exercise Prices Shares Weighted Options: $18.75 293 5.52 $65.75 10,019 9.81 $73.50 1,225 10.01 $77.50 2,387 9.50 $80.25 250 9.76 $86.25 289 9.25 $121.88 6 7.20 $131.25 82 6.69 $140.63 7,679 7.21 $148.13 929 7.22 $150.00 4,959 6.63 $162.50 153 9.01 $206.25 145 8.76 $248.44 120 7.54 $262.50 130 7.54 $281.25 546 7.09 $318.75 3 7.36 $346.88 87 8.25 $431.25 1,610 8.19 $468.75 134 8.15 $506.25 198 8.01 $543.75 54 7.77 $596.25 51 7.75 Total 31,349 Warrants: $123.75 303,081 4.67 $150.00 4,114 2.20 $225.00 107 2.07 $243.75 2,529 3.59 $281.25 8,152 2.02 $309.38 2,850 3.61 $309.50 222 3.85 $337.50 178 2.47 $371.25 944 2.41 $506.25 59 3.13 $609.38 861 3.10 Total 323,098 Stock options and warrants expire on various dates from June 2017 to December 2025. On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 4,000,000 shares of common stock and the authorized preferred stock was increased to 20,000,000 shares. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2015 by year of grant: Stock Options: Year Shares Price 2011 467 18.75 2012 5,041 131.25 – 150.00 2013 9,310 121.88 – 596.25 2014 2,361 162.50 – 468.75 2015 14,170 65.75 – 86.25 Total 31,349 $ 18.75 – 596.25 Warrants: Year Shares Price 2012 2,792 281.25 – 375.00 2013 10,703 150.00 – 371.25 2014 6,455 309.38 – 609.38 2015 303,148 123.75 Total 323,098 $ 123.75 – 609.38

Note 4 - Short-term Notes Pay30

Note 4 - Short-term Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $1.8 million original principal amount (subsequently reduced to approximately $1.6 million aggregate principal amount in accordance with their terms) of convertible promissory notes (the “2014 Convertible Notes”) and warrants exercisable for shares of our common stock for an aggregate purchase price of $1,475,000. Of this amount, we issued to SOK Partners, LLC, an affiliate of the Company, $122,196 original principal amount of the 2014 Convertible Notes and warrants exercisable for 218 shares of our common stock for an aggregate purchase price of $100,000. In April and May 2015, we issued and sold to a private investor additional Convertible Notes in an aggregate original principal amount of $275,000 for an aggregate purchase price of $250,000, containing terms substantially similar to the 2014 Convertible Notes (the “2015 Convertible Notes” and, together with the 2014 Convertible Notes, the “Convertible Notes”). No warrants were issued with the 2015 Convertible Notes. Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11%, to $1,603,260 and the number of Warrants was reduced by 11%, to 2,851 shares. As of September 30, 2016 $927,663 aggregate principal amount of Convertible Notes, plus accrued and unpaid interest thereto, have been converted into shares of our common stock and no aggregate principal amount of Convertible Notes remains outstanding. In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% of the principal amount, plus accrued and unpaid interest to the redemption date. On August 31, 2015, the closing date of the offering, the Company redeemed the remaining $933,074 aggregate principal amount of Convertible Notes plus interest and a 40% redeemable premium, for a total payment of $1,548,792. Of this amount, approximately $167,031 was paid to its affiliates in redemption of their Convertible Notes. Each holder of the Convertible Notes agreed to the foregoing terms and entered into an Amendment to Senior Convertible Notes and Agreement with the Company. As of September 30, 2016, none of the Convertible Notes were outstanding.	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $1.8 million original principal amount (subsequently reduced to approximately $1.6 million aggregate principal amount in accordance with their terms) of convertible promissory notes (the “2014 Convertible Notes”) and warrants exercisable for shares of our common stock for an aggregate purchase price of $1,475,000. Of this amount, we issued to SOK Partners, LLC, an affiliate of the Company, $122,196 original principal amount of the 2014 Convertible Notes and warrants exercisable for 218 shares of our common stock for an aggregate purchase price of $100,000. In April and May 2015, we issued and sold to a private investor additional Convertible Notes in an aggregate original principal amount of $275,000 for an aggregate purchase price of $250,000, containing terms substantially similar to the 2014 Convertible Notes (the “2015 Convertible Notes” and, together with the 2014 Convertible Notes, the “Convertible Notes”). No warrants were issued with the 2015 Convertible Notes. Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11%, to $1,603,260 and the number of Warrants was reduced by 11%, to 2,851 shares. As of June 30, 2015, $927,663 aggregate principal amount of Convertible Notes, plus accrued and unpaid interest thereto, have been converted into shares of our common stock and $933,073 aggregate principal amount of Convertible Notes remained outstanding. In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% of the principal amount, plus accrued and unpaid interest to the redemption date. On August 31, 2015, the closing date of the offering, the Company redeemed the remaining $933,074 aggregate principal amount of Convertible Notes plus interest and a 40% redeemable premium, for a total payment of $1,548,792. Of this amount, approximately $167,031 was paid to its affiliates in redemption of their Convertible Notes. Each holder of the Convertible Notes agreed to the foregoing terms and entered into an Amendment to Senior Convertible Notes and Agreement with the Company. As of December 31, 2015 none of the Convertible Notes were outstanding.

Note 5 - Loss Per Share31

Note 5 - Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (1,055,593 ) $ (1,116,402 ) $ (5,793,242 ) $ (2,527,524 ) Other comprehensive income: Unrealized gain (loss) from marketable securities (1,299 ) - 4,579 - Comprehensive (loss) (1,056,892 ) (1,116,402 ) (5,788,663 ) (2,527,524 ) Denominator: Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Loss per common share-basic and diluted $ (0.32 ) $ (7.09 ) $ (2.57 ) $ (18.39 ) (1) The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 155,234 119,619 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 155,234 119,619 Loss per common share-basic and diluted $ (30.86 ) $ (57.13 ) (1) The number of shares underlying options and warrants outstanding as of December 31, 2015 and December 31, 2014 are 354.447 and 37,972, respectively. The number of shares underlying the preferred stock as of December 31, 2015 is 75,921. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes32

Note 6 - Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6 – INCOME TAXES Availability and Utilization of Net Operating Losses During September 2013, the Company experienced an “ownership change” as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. During the first quarter of 2016, the Company likely had another ownership change that could further limit the Company’s ability to fully utilize its NOLs however, the determination of the annual limitation has not yet been made. Income Taxes At December 31, 2015, the Company had approximately $24.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2016, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $13.4 million of gross NOLs to reduce future state taxable income at December 31, 2015, which will expire in years 2022 through 2036 if unused. The Company’s net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2015, the federal and state valuation allowances were $9.6 million and $1.1 million, respectively. At September 30, 2016, the Company had approximately $29.2 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2017, subject to the Section 382 limitations described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $15.0 million of gross NOLs to reduce future state taxable income at September 30, 2016, which will expire in years 2022 through 2037 if unused. The Company’s net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At September 30, 2016, the federal and state valuation allowances were $10.1 million and $0.3 million, respectively. The components of deferred income taxes at September 30, 2016 and December 31, 2015 are as follows: September 30, December 31, Deferred Tax Asset: Net Operating Loss $ 10,271,000 $ 10,338,000 Other 166,000 359,000 Total Deferred Tax Asset 10,437,000 10,697,000 Less Valuation Allowance 10,437,000 10,697,000 Net Deferred Income Taxes $ — $ —	NOTE 6– INCOME TAXES The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate. During September 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. At December 31, 2014, the Company had approximately $18.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $12.4 million of gross NOLs to reduce future state taxable income at December 31, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2014, the federal and state valuation allowances were $8.1 million and $1.0 million, respectively. At December 31, 2015, the Company had approximately $24.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2016, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $13.4 million of gross NOLs to reduce future state taxable income at December 31, 2015, which will expire in years 2022 through 2035 if unused. The Company’s net deferred tax assets, which include the NOLs are subject to a full valuation allowance. At December 31, 2015, the federal and state valuation allowances were $9.6 million and $1.1 million, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2015 and December 31, 2014 are as follows: December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation33

Note 7 - Rent Obligation	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $16,356 and $50,106 for the three and nine months ended September 30, 2016 and was $15,900 and $50,156 for the three and nine months ended September 30, 2015 respectively. The Company’s rent obligation for the next three years is as follows: 2016 $ 9,500 2017 $ 39,000 2018 $ 3,600	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $66,345 and $64,753 for 2015 and 2014, respectively. The Company’s rent obligation for the next three years are as follows: 2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In connection with the sale of the Series A Preferred Share on February 4, 2014, Josh Kornberg, our former, and then President, CEO and Interim Chairman of the Board, was one of the Purchasers. Mr. Kornberg purchased 770 Preferred Shares for a purchase price of $25,000 and received warrants to purchase 3 shares of common stock. SOK Partners, LLC (“SOK”), a large stockholder with Mr. Kornberg and Dr. Samuel Herschkowitz as managing partners, invested in the July 2014 offering of convertible notes and warrants. In November 2014, the convertible noteholders agreed to convert certain balances of the convertible notes in connection with the public offering of the Existing Units, in consideration of the agreement to issue certain additional shares. See “Management’s Discussion and Analysis of Financial Conditions and Results of Operations – Liquidity and Capital Resources – History Financing – 2014 Sales of Convertible Notes and Warrants.” In connection with the Unit Offering in August 2015, all such convertible notes were redeemed at a redemption price of 140% of the principal amount thereof, plus accrued and unpaid interest. The Company paid approximately $163,000 to SOK in redemption of its convertible note. In addition, Rick Koenigsberger, a former director who resigned on June 5, 2015, is a holder of membership units of SOK Partners. In connection with the Unit Exchange that was consummated on August 31, 2015, 250 shares of Series A Convertible Stock held by Mr. Kornberg were exchanged for 2,778 Exchange Units.	NOTE 9 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners. In connection with the sale of the Series A Preferred Shares on February 4, 2014, Joshua Kornberg, our President, Chief Executive Officer and Interim Chairman of the Board, was one of the purchasers. Mr. Kornberg purchased 19,231 Series A Preferred Shares for a purchase price of $25,000 and received warrants to purchase 3 shares of common stock. SOK Partners, LLC (“SOK”), a 10% stockholder with Mr. Kornberg and Dr. Samuel Herschkowitz as managing partners, invested in the July 2014 offering of convertible notes and warrants. In November 2014, the convertible noteholders agreed to convert certain balances of the convertible notes in connection with the public offering of the Existing Units, in consideration of the agreement to issue certain additional shares. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – History Financing – 2014 Sales of Convertible Notes and Warrants.” In connection with the Unit Offering in August 2015, all such convertible notes were redeemed at a redemption price of 140% of the principal amount thereof, plus accrued and unpaid interest. The Company paid approximately $163,000 to SOK in redemption of its convertible note. In addition, Ricardo Koenigsberger, a former director who resigned on June 5, 2015, is a holder of membership units of SOK Partners. In connection with the Unit Exchange that was consummated on August 31, 2015, 250 shares of Series A Convertible Stock held by Mr. Kornberg were exchanged for 2,778 Exchange Units.

Note 9 - Retirement Savings Pla

Note 9 - Retirement Savings Plan	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 – RETIREMENT SAVINGS PLAN We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2016 and 2015, we matched 100%, of the employee’s contribution up to 4% of their earnings. The employer contribution was $7,401 and $28,196 for the three and nine months ending September 30, 2016 and was $7,021 and $21,735 for the three and nine months ending September 30, 2015, respectively.	NOTE 10 – RETIREMENT SAVINGS PLANS We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2014, and again in 2015, we matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $39,916 and $37,730 in 2015 and 2014. There were no discretionary contributions to the plan in 2015 and 2014.

Note 10 - Supplemental Cash Flo

Note 10 - Supplemental Cash Flow Data	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 10 – SUPPLEMENTAL CASH FLOW DATA There were $3 in cash payments for interest for the three and nine months ended September 30, 2016 and were $226,960 and $237,121 for the three and nine months ended September 30, 2015.	NOTE 11 – SUPPLEMENTAL CASH FLOW DATA Cash payments for interest were $246,620 and $47,111 for the fiscal years ended December 31, 2015 and December 31, 2014, respectively.

Note 11 - Investment Securities

Note 11 - Investment Securities and Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Investment Securities and Other Comprehensive Income/(Loss) [Text Block]	NOTE 11 – INVESTMENT SECURITIES AND OTHER COMPREHENSIVE INCOME (LOSS) The cost and fair values of investment securities available-for-sale at September 30, 2016 were as follows: September 30, 2016 Description Cost Gross Gross Fair Value Mutual Funds $ 572,309 $ 4,579 $ - $ 576,888

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations On October 27, 2016, the Company effected a 1-for-25 reverse stock split of its common stock. All share information in the financial statements for fiscal years 2016 and 2015 reflect the impact of the reverse stock split. Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of September 30, 2016, the registrant had 3,404,860 shares of common stock, par value $.01 per share, outstanding. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY® FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to September 30, 2016, the Company raised approximately $22,325,091 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”	Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of December 31, 2015, the registrant had 208,259 shares of common stock, par value $.01 per share, outstanding, adjusted for a 1-for-75 reverse stock split effective October 24, 2014, and then a 1-for-25 reverse stock split effective October 27, 2016. In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the both reverse stock splits. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to December 31, 2015, the Company raised approximately $22,732,961 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. Debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts, rather than as an asset. Amortization of these costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual and interim reporting periods beginning after December 15, 2015. Early adoption is permitted. The adoption of this ASU is not expected to have an impact on our financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. We are currently evaluating the impact this guidance may have on our financial statements. In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” providing guidance on the balance sheet classification of deferred taxes. The guidance requires that deferred tax assets and liabilities to be classified as noncurrent in the Balance Sheet. The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842 In March 2016, the FASB issued ASU No. 2016-09, “ Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accountin During August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.	Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11 , Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation of Taxes Collected From Customers, Policy [Policy Text Block]	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $10,343 and $57,004 in the three and nine months ended September 30, 2016 and were $500 and $1,917 in the three and nine months ended September 30, 2015.	Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $79,936 and $302,330 in the three and nine months ended September 30, 2016 and were $58,792 and $179,739 in the three and nine months ended September 30, 2015.	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of filters and fluids. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution or filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.	Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.
Receivables, Policy [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: September 30, December 31, Finished goods $ 72,540 $ 30,237 Raw materials 157,044 162,623 Work-In-Process 59,665 38,880 Total $ 289,249 $ 231,740	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: September 30, December 31, Computers and office equipment $ 164,319 $ 153,553 Leasehold improvements 25,635 23,874 Manufacturing tooling 101,104 97,288 Demo Equipment 17,702 8,962 Total 308,760 283,677 Less: Accumulated depreciation 197,850 144,079 Total Fixed Assets, Net $ 110,910 $ 139,598 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2015 December 31, 2014 Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $2,515 and $6,225 in the three and nine months ended September 30, 2016, and was $1,632 and $4,520 in the three and nine months ended September 30, 2015. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.	Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities.	Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications.	Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company has a credit risk concentration as a result of depositing $454,369 of funds in excess of insurance limits in a single bank.	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs In the three and nine months ending September 30, 2016 the incurred approximately $2,102 and $33,083 in current warranty costs and incurred $12,084 and $39,688 in warranty costs for the three and nine months ending September 30, 2015.	Product Warranty Costs In 2015, the Company incurred approximately $56,201 in current warranty costs.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues and expenses for the three and nine months ending September 30, 2016 and for 2015 in entirety were located at or derived from operations in the United States. There were no revenue from sales outside of the United States. The Company has recently attained its ISO 13485 certification and is applying to sell our products in Canada.	Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for 2015 and 2014 were located at or derived from operations in the United States. There were no revenues from sales outside of the United States.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one year but greater than three months when purchased. Certificates with maturity dates beyond one year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.
Marketable Securities, Policy [Policy Text Block]	Investment Securities Readily marketable investments in debt and equity securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions. The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 inputs.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company filed a Certificate of Amendment effecting a 1:25 reverse stock split (the “Reverse Stock Split” with the Secretary of State of the State of Delaware, which became effective under Delaware law at 5:00 p.m. New York time on October 27, 2016. The Company’s common stock opened for trading on October 28, 2016 on a post-split basis. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-25 basis such that every twenty-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. The share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination.
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 16, 2016. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Note 1 - Summary of Significa39

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, Finished goods $ 72,540 $ 30,237 Raw materials 157,044 162,623 Work-In-Process 59,665 38,880 Total $ 289,249 $ 231,740	December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	September 30, December 31, Computers and office equipment $ 164,319 $ 153,553 Leasehold improvements 25,635 23,874 Manufacturing tooling 101,104 97,288 Demo Equipment 17,702 8,962 Total 308,760 283,677 Less: Accumulated depreciation 197,850 144,079 Total Fixed Assets, Net $ 110,910 $ 139,598	December 31, 2015 December 31, 2014 Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479

Note 3 - Stockholders' Equity40

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 100,837 3.329 730,882 1.44 Expired (22,377 ) 122.132 - - Exercised (1,312 ) 65.750 (939,879 ) - Outstanding at September 30, 2016 108,498 $ 15.652 114,102 $ 369.06	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2013 15,430 $ 168.75 18,477 $ 262.50 Issued 3,028 203.00 6,455 95.25 Expired (316 ) 589.50 (3,275 ) 338.50 Exercised (198 ) 44.00 (1,629 ) 209.50 Outstanding at December 31, 2014 17,944 $ 187.75 20,028 $ 198.75 Issued 14,171 69.00 303,269 123.75 Cancelled (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,349 $ 133.25 323,098 $ 128.50
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 2.25 293 9.90 $ 2.42 37,152 9.89 $ 3.75 44,000 9.76 $ 4.125 3,636 10.00 $ 4.1975 7,147 9.97 $ 4.25 3,529 9.50 $ 5.125 3,902 9.94 $ 65.75 342 9.06 $ 73.50 1,157 9.26 $ 77.50 2,323 8.75 $ 80.25 187 9.01 $ 86.25 232 8.50 $ 121.875 5 6.45 $ 131.25 81 5.94 $ 148.125 928 6.47 $ 150.00 1,760 5.88 $ 162.50 123 8.26 $ 206.25 121 8.01 $ 248.4375 121 6.79 $ 262.50 130 6.79 $ 281.25 529 6.30 $ 318.75 3 6.60 $ 346.875 72 7.50 $ 431.25 306 7.44 $ 468.75 133 7.40 $ 506.25 188 7.25 $ 543.75 53 7.02 $ 596.25 42 7.00 108,498 Warrants $ 93.75 2,255 1.45 $ 123.75 94,084 3.92 $ 150.00 4,114 1.45 $ 225.00 107 1.32 $ 243.75 2,529 2.84 $ 281.25 5,897 1.20 $ 309.375 2,850 2.86 $ 309.50 222 3.10 $ 337.50 178 1.72 $ 371.25 944 1.66 $ 506.25 59 2.38 $ 609.375 862 2.34 114,102	Range of Exercise Prices Shares Weighted Options: $18.75 293 5.52 $65.75 10,019 9.81 $73.50 1,225 10.01 $77.50 2,387 9.50 $80.25 250 9.76 $86.25 289 9.25 $121.88 6 7.20 $131.25 82 6.69 $140.63 7,679 7.21 $148.13 929 7.22 $150.00 4,959 6.63 $162.50 153 9.01 $206.25 145 8.76 $248.44 120 7.54 $262.50 130 7.54 $281.25 546 7.09 $318.75 3 7.36 $346.88 87 8.25 $431.25 1,610 8.19 $468.75 134 8.15 $506.25 198 8.01 $543.75 54 7.77 $596.25 51 7.75 Total 31,349 Warrants: $123.75 303,081 4.67 $150.00 4,114 2.20 $225.00 107 2.07 $243.75 2,529 3.59 $281.25 8,152 2.02 $309.38 2,850 3.61 $309.50 222 3.85 $337.50 178 2.47 $371.25 944 2.41 $506.25 59 3.13 $609.38 861 3.10 Total 323,098
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year Shares Price 2011 173 0.00 - 281.25 2012 1,841 131.25 - 150.00 2013 1,612 121.88 - 596.25 2014 969 162.50 - 468.75 2015 4,240 65.75 - 86.25 2016 99,661 2.25 - 5.13 Total 108,498 $0.00 - 596.25 Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 - 609.38 2015 94,152 0.00 - 243.75 Total 114,102 $0.00 - 609.38	Year Shares Price 2011 467 18.75 2012 5,041 131.25 – 150.00 2013 9,310 121.88 – 596.25 2014 2,361 162.50 – 468.75 2015 14,170 65.75 – 86.25 Total 31,349 $ 18.75 – 596.25 Year Shares Price 2012 2,792 281.25 – 375.00 2013 10,703 150.00 – 371.25 2014 6,455 309.38 – 609.38 2015 303,148 123.75 Total 323,098 $ 123.75 – 609.38

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (1,055,593 ) $ (1,116,402 ) $ (5,793,242 ) $ (2,527,524 ) Other comprehensive income: Unrealized gain (loss) from marketable securities (1,299 ) - 4,579 - Comprehensive (loss) (1,056,892 ) (1,116,402 ) (5,788,663 ) (2,527,524 ) Denominator: Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Loss per common share-basic and diluted $ (0.32 ) $ (7.09 ) $ (2.57 ) $ (18.39 )	Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 155,234 119,619 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 155,234 119,619 Loss per common share-basic and diluted $ (30.86 ) $ (57.13 )

Note 6 - Income Taxes (Tables)

Note 6 - Income Taxes (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	September 30, December 31, Deferred Tax Asset: Net Operating Loss $ 10,271,000 $ 10,338,000 Other 166,000 359,000 Total Deferred Tax Asset 10,437,000 10,697,000 Less Valuation Allowance 10,437,000 10,697,000 Net Deferred Income Taxes $ — $ —	December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation (Table

Note 7 - Rent Obligation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Rent Expense [Table Text Block]	2016 $ 9,500 2017 $ 39,000 2018 $ 3,600	2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 8 - Liability for Equity44

Note 8 - Liability for Equity-linked Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Stock price $93.75 to $937.50 Exercise price $18.75 to $609.50 Expected life (years) 2.0 to 6.5 Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13% to 2.97%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 2012 Gain Value 2013 Gain Value 2014 Gain Value at January 1, 2009 adoption $ 479,910 $ (390,368 ) $ 870,278 $ 868,772 $ 1,506 $ (88,290 ) $ 89,796 $ (21,856 ) $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 6/30/2009 169,854 20,847 149,007 147,403 1,604 (4,689 ) 6,293 6,293 - - - - - Warrants issued in quarter ended 9/30/2009 39,743 (738 ) 40,481 40,419 62 (1,562 ) 1,624 910 714 714 - - - Warrants is used in quarter ended 12/31/2009 12,698 617 12,081 12,053 28 (724 ) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 3/31/2010 25,553 25,014 539 (5,570 ) 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 6/30/2010 31,332 30,740 592 (6,122 ) 6,714 6,083 631 631 - - - Warrants issued in quarter ended 9/30/2010 31,506 20,891 10,615 (44,160 ) 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 ) $ 1,071,847 $ 1,145,292 $ 14,946 $ (151,117 ) $ 166,063 $ (3,116 ) $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

Note 1 - Summary of Significa45

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, Finished goods $ 72,540 $ 30,237 Raw materials 157,044 162,623 Work-In-Process 59,665 38,880 Total $ 289,249 $ 231,740	December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	September 30, December 31, Computers and office equipment $ 164,319 $ 153,553 Leasehold improvements 25,635 23,874 Manufacturing tooling 101,104 97,288 Demo Equipment 17,702 8,962 Total 308,760 283,677 Less: Accumulated depreciation 197,850 144,079 Total Fixed Assets, Net $ 110,910 $ 139,598	December 31, 2015 December 31, 2014 Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479

Note 3 - Stockholders' Defici46

Note 3 - Stockholders' Deficit, Stock Options and Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 100,837 3.329 730,882 1.44 Expired (22,377 ) 122.132 - - Exercised (1,312 ) 65.750 (939,879 ) - Outstanding at September 30, 2016 108,498 $ 15.652 114,102 $ 369.06	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2013 15,430 $ 168.75 18,477 $ 262.50 Issued 3,028 203.00 6,455 95.25 Expired (316 ) 589.50 (3,275 ) 338.50 Exercised (198 ) 44.00 (1,629 ) 209.50 Outstanding at December 31, 2014 17,944 $ 187.75 20,028 $ 198.75 Issued 14,171 69.00 303,269 123.75 Cancelled (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,349 $ 133.25 323,098 $ 128.50
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 2.25 293 9.90 $ 2.42 37,152 9.89 $ 3.75 44,000 9.76 $ 4.125 3,636 10.00 $ 4.1975 7,147 9.97 $ 4.25 3,529 9.50 $ 5.125 3,902 9.94 $ 65.75 342 9.06 $ 73.50 1,157 9.26 $ 77.50 2,323 8.75 $ 80.25 187 9.01 $ 86.25 232 8.50 $ 121.875 5 6.45 $ 131.25 81 5.94 $ 148.125 928 6.47 $ 150.00 1,760 5.88 $ 162.50 123 8.26 $ 206.25 121 8.01 $ 248.4375 121 6.79 $ 262.50 130 6.79 $ 281.25 529 6.30 $ 318.75 3 6.60 $ 346.875 72 7.50 $ 431.25 306 7.44 $ 468.75 133 7.40 $ 506.25 188 7.25 $ 543.75 53 7.02 $ 596.25 42 7.00 108,498 Warrants $ 93.75 2,255 1.45 $ 123.75 94,084 3.92 $ 150.00 4,114 1.45 $ 225.00 107 1.32 $ 243.75 2,529 2.84 $ 281.25 5,897 1.20 $ 309.375 2,850 2.86 $ 309.50 222 3.10 $ 337.50 178 1.72 $ 371.25 944 1.66 $ 506.25 59 2.38 $ 609.375 862 2.34 114,102	Range of Exercise Prices Shares Weighted Options: $18.75 293 5.52 $65.75 10,019 9.81 $73.50 1,225 10.01 $77.50 2,387 9.50 $80.25 250 9.76 $86.25 289 9.25 $121.88 6 7.20 $131.25 82 6.69 $140.63 7,679 7.21 $148.13 929 7.22 $150.00 4,959 6.63 $162.50 153 9.01 $206.25 145 8.76 $248.44 120 7.54 $262.50 130 7.54 $281.25 546 7.09 $318.75 3 7.36 $346.88 87 8.25 $431.25 1,610 8.19 $468.75 134 8.15 $506.25 198 8.01 $543.75 54 7.77 $596.25 51 7.75 Total 31,349 Warrants: $123.75 303,081 4.67 $150.00 4,114 2.20 $225.00 107 2.07 $243.75 2,529 3.59 $281.25 8,152 2.02 $309.38 2,850 3.61 $309.50 222 3.85 $337.50 178 2.47 $371.25 944 2.41 $506.25 59 3.13 $609.38 861 3.10 Total 323,098
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year Shares Price 2011 173 0.00 - 281.25 2012 1,841 131.25 - 150.00 2013 1,612 121.88 - 596.25 2014 969 162.50 - 468.75 2015 4,240 65.75 - 86.25 2016 99,661 2.25 - 5.13 Total 108,498 $0.00 - 596.25 Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 - 609.38 2015 94,152 0.00 - 243.75 Total 114,102 $0.00 - 609.38	Year Shares Price 2011 467 18.75 2012 5,041 131.25 – 150.00 2013 9,310 121.88 – 596.25 2014 2,361 162.50 – 468.75 2015 14,170 65.75 – 86.25 Total 31,349 $ 18.75 – 596.25 Year Shares Price 2012 2,792 281.25 – 375.00 2013 10,703 150.00 – 371.25 2014 6,455 309.38 – 609.38 2015 303,148 123.75 Total 323,098 $ 123.75 – 609.38

Note 5 - Loss Per Share (Tabl47

Note 5 - Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (1,055,593 ) $ (1,116,402 ) $ (5,793,242 ) $ (2,527,524 ) Other comprehensive income: Unrealized gain (loss) from marketable securities (1,299 ) - 4,579 - Comprehensive (loss) (1,056,892 ) (1,116,402 ) (5,788,663 ) (2,527,524 ) Denominator: Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 3,320,139 157,445 2,250,315 137,428 Loss per common share-basic and diluted $ (0.32 ) $ (7.09 ) $ (2.57 ) $ (18.39 )	Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 155,234 119,619 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 155,234 119,619 Loss per common share-basic and diluted $ (30.86 ) $ (57.13 )

Note 6 - Income Taxes (Tables48

Note 6 - Income Taxes (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	September 30, December 31, Deferred Tax Asset: Net Operating Loss $ 10,271,000 $ 10,338,000 Other 166,000 359,000 Total Deferred Tax Asset 10,437,000 10,697,000 Less Valuation Allowance 10,437,000 10,697,000 Net Deferred Income Taxes $ — $ —	December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation (Tab49

Note 7 - Rent Obligation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Rent Expense [Table Text Block]	2016 $ 9,500 2017 $ 39,000 2018 $ 3,600	2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 11 - Investment Securiti50

Note 11 - Investment Securities and Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	September 30, 2016 Description Cost Gross Gross Fair Value Mutual Funds $ 572,309 $ 4,579 $ - $ 576,888

Note 1 - Summary of Significa51

Note 1 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended		166 Months Ended	177 Months Ended
	Sep. 30, 2016USD ($)shares	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)shares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2015USD ($)shares	Sep. 30, 2016USD ($)shares
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues							$ 2,055,000	$ 2,055,000
IPO [Member]
Stock Issued During Period, Value, New Issues							$ 13,555,003	$ 13,555,003
Earliest Tax Year [Member]
Open Tax Year			2,012		2,012
Non-US [Member]
Revenues					$ 0	$ 0
Common Stock, Shares, Outstanding | shares	3,404,860		3,404,860		208,259	123,711	208,259	3,404,860
Stockholders' Equity, Period Increase (Decrease)			$ 22,325,091				$ 22,732,961
Stock Issued During Period, Value, New Issues					$ 13,060,880	$ 2,055,001
Debt Instrument, Increase (Decrease), Net							5,685,000	$ 5,685,000
Advertising Expense	$ 10,343	$ 500	57,004	$ 1,917	8,220	19,394
Research and Development Expense	79,936	58,792	302,330	179,739	261,000	$ 394,000
Cash, Uninsured Amount	454,369		454,369		4,621,764		$ 4,621,764	$ 454,369
Product Warranty Expense	$ 2,102	$ 12,084	$ 33,083	$ 39,688	$ 56,201
Number of Operating Segments			1		1

Note 1 - Summary of Significa52

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Finished goods	$ 72,540	$ 30,237	$ 88,362
Raw materials	157,044	162,623	237,556
Work-In-Process	59,665	38,880	41,449
Total	$ 289,249	$ 231,740	$ 367,367

Note 1 - Summary of Significa53

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life	3 years	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life	3 years	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life	7 years	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life	7 years	7 years
Leasehold Improvements [Member]
Property, plant, and equipment, useful life	5 years	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life	3 years	3 years

Note 1 - Summary of Significa54

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Office Equipment [Member]
Property, Plant, and Equipment Gross	$ 164,319	$ 153,553	$ 123,708
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	25,635	23,874	23,874
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	101,104	97,288	97,288
Demo Equipment [Member]
Property, Plant, and Equipment Gross	17,702	8,962	30,576
Property, Plant, and Equipment Gross	308,760	283,677	275,446
Less: Accumulated Depreciation	197,850	144,079	78,967
Total Fixed Assets, Net	$ 110,910	$ 139,598	$ 196,479

Note 2 - Development Stage Op55

Note 2 - Development Stage Operations (Details Textual) - $ / shares	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2009
Common Stock [Member]
Share Price		$ 3,131.25
Common Stock, Shares, Issued		208,259
Share Price	$ 4.125		$ 656.25

Note 3 - Stockholders' Equity56

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) - USD ($)	Oct. 04, 2016	Mar. 11, 2016	Aug. 31, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Sep. 14, 2014	Sep. 09, 2014	Jun. 30, 2014	Mar. 31, 2014	Feb. 04, 2014	Jun. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Nov. 30, 2014	Sep. 30, 2014	Aug. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jan. 31, 2014	Mar. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2014	Oct. 24, 2016	Sep. 16, 2016	Jul. 24, 2015	Jul. 31, 2014	Feb. 28, 2014
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued			228,343
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage			5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase			83,333
Unit Purchase Option Exercise Price, Percentage			125.00%
Unit Purchase Option Exercise Price			$ 11.25
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			75,800
Exchange Units [Member] | Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			1,895,010
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			7,580,040
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			3,391
Exchange Units [Member]
Unit Purchase Option Units Sold			1,666,667
Unit Purchase Option Units Issued			228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities			1,895,010
Employee, Director and Consultant Stock Options [Member] | Maximum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																										3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																										10 years
Employee, Director and Consultant Stock Options [Member] | Minimum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																										3 years
Maximum [Member] | Common Stock [Member]
Share Price																														$ 3,131.25
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter			$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																								$ 609.38		$ 609.38
Share Price						$ 937.50										$ 937.50											$ 937.50		$ 937.50
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																								1.78%		2.35%	2.75%		2.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																								10 years		10 years	10 years		6 years 182 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																								$ 596.25		$ 139.2386	$ 347.9864
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term																										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																								3.7195		$ 139.24
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																								$ 0		$ 123.75
Share Price						93.75										93.75											$ 93.75		$ 93.75
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																								1.46%		1.63%	1.44%		0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																										5 years	5 years		2 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																								$ 0		$ 6.8745	$ 80.015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																								$ 1.6329		6.88
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Subsequent Event [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period Shares Warrants Exercised		1,685,229
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.4
Warrants Option to Settle in Cash Fair Value Disclosure		$ 108.115
Class of Warrant or Right Exercised During Period		3,390,935
Stock Issued During Period Shares Warrants Exercised		1,362,147
Class of Warrant or Right, Outstanding		4,189,105
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period Shares Warrants Exercised																								564
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member]
Unit Agreement Number of Warrants Included in Each Unit			4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1																					0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.95
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise			2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula		$ 0.43	$ 10.75
Warrants Option to Settle in Cash Fair Value Disclosure																								$ 108.115
Class of Warrant or Right Exercised During Period																								6,141,115
Stock Issued During Period Shares Warrants Exercised																								2,318,663
Class of Warrant or Right, Outstanding			35,084
Beneficial Ownership Limitation Percentage			4.99%
Class of Warrant or Right Period Over Which Additional Adjustments to Price and Number of Shares May Be Made			3 years
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Preferred Stock Included in Each Unit			1
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Warrants Included in Each Unit			4
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit			1
Common Stock, Par or Stated Value Per Share			$ 0.01
Common Stock [Member]
Share Price																										$ 3,131.25
Stock Issued During Period Shares Warrants Exercised																								2,318,663		120
Stock Issued During Period, Value, New Issues																										$ 667
Stock Issued During Period, Shares, New Issues																										66,667				3,804,860
Stock Issued During Period, Value, Stock Options Exercised																								$ 13
Stock Issued During Period Shares Preferred Stock Conversion																								66,396		9,134
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																								1,312
Warrant [Member]
Cashless Exercise of Common Stock Warrants, Total																							618
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage			4.99%
Convertible Preferred Stock, Shares Issued upon Conversion			1
Stock Issued During Period, Value, New Issues												$ 2,055,000
Stock Issued During Period, Shares, New Issues												20,550
Preferred Stock Par Value												$ 0.01
Preferred Stock Stated Value												$ 100
Preferred Stock, Par or Stated Value Per Share						$ 0.01										$ 0.01								$ 0.01		$ 0.01	$ 0.01		$ 0.01
Preferred Stock, Shares Authorized						10,000,000										10,000,000								20,000,000		20,000,000	10,000,000		10,000,000
Series A Convertible Preferred Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																																		$ 609.50
Stock Issued During Period, Value, New Issues												$ 2,055,000
Stock Issued During Period, Shares, New Issues												20,550
Preferred Stock Par Value												$ 0.01
Preferred Stock Stated Value						$ 100						$ 100				$ 100										$ 100	$ 100		$ 100
Preferred Stock, Par or Stated Value Per Share						$ 0.01										$ 0.01										$ 0.01	$ 0.01		$ 0.01
Preferred Stock, Shares Authorized						10,000,000										10,000,000										10,000,000	10,000,000		10,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share	$ 0.01
Share Price		$ 4.50
Stock Issued During Period, Shares, New Issues	400,000
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount			$ 933,074
Debt Instrument Redemption Premium Percentage			40.00%
Debt Instrument Redemption Price			$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates			$ 167,031
Chief Executive Officer [Member]
Stock Issued During Period, Value, Stock Options Exercised																						$ 174
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price																						$ 31.25
Dr.Samuel Herschkowitz [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																																		$ 506.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																		60
Two Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																																	$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	1,160
Purchasers [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities				125	125	63							125	125	125	63		63
Class of Warrant or Right, Exercise Price of Warrants or Rights																			$ 609.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			2,462
Preferred Stock, Dividend Rate, Percentage				6.00%	6.00%	6.00%	6.00%						6.00%	6.00%		6.00%		6.00%
Preferred Stock Conversion Price Per Share							$ 487.50								$ 487.50	$ 487.50		$ 487.50
Stock Issued During Period Shares Preferred Stock Conversion							63
Number of Preferred Stock Share holders				16	16	16	16						16	16	16	16		16									16		16
Preferred Stock, Par or Stated Value Per Share						$ 487.50										$ 487.50											$ 487.50		$ 487.50
Maximum Number of Days Not Listed on Stock Market																			180 days
Conversion of Stock Price Per Share				$ 243.75	$ 243.75								$ 243.75	$ 243.75	$ 243.75
Four Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 309.50											$ 309.50	$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,498											1,498	1,498
SOK Partners LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 309.50	$ 309.50										$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									194	218										218
Percentage of Reduction to Warrant Agreement								11.00%	11.00%
Option Granted to Underwriter to Purchase Additional Units Additional Units Purchased			0
Shares Issued, Price Per Share			$ 9
Underwriter Price			8.28
Underwriting Discount			$ 0.72
Underwriting Commission			8.00%
Proceeds from Issuance or Sale of Equity			$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period			45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted			250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage			1.00%
Common Stock, Par or Stated Value Per Share						$ 0.01										$ 0.01	$ 0.01							$ 0.01		$ 0.01	$ 0.01		$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 281.25										$ 281.25		$ 281.25
Share Price																								$ 4.125				$ 656.25
Class of Warrant or Right, Outstanding																								114,102		323,098
Stock Issued During Period, Value, New Issues																										$ 13,060,880	$ 2,055,001
Stock Issued During Period, Shares, New Issues			1,666,667														548
Stock Issued During Period, Value, Stock Options Exercised																								$ 86,253
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price																								$ 65.75
Cashless Exercise of Common Stock Warrants, Total											134										134
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																						862												862
Preferred Stock, Dividend Rate, Percentage										6.00%	6.00%
Preferred Stock Conversion Price Per Share										$ 487.50	$ 487.50
Stock Issued During Period Shares Preferred Stock Conversion										63	39
Number of Preferred Stock Share holders										16	16									16	16		16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											178									149	178
Preferred Stock, Par or Stated Value Per Share										$ 487.50										$ 487.50
Percentage Reduction to Number of Warrants							11.00%		11.00%									11.00%															11.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																												1.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																								0.00%		0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																										59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																								66.00%		66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																												2 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																								64,542		31,229
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price																								$ 23.46		$ 132.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																								9 years 208 days		8 years 62 days
Class of Warrant or Right Number of Warrants Vested and Exercisable																										323,098
Allocated Share-based Compensation Expense																								$ 1,393,862	$ 320,334	$ 871,877	$ 723,367
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options																								$ 132,675		$ 32,682
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																										60 days
Common Stock, Shares Authorized						4,000,000										4,000,000								8,000,000		8,000,000	4,000,000		4,000,000		8,000,000	4,000,000
Preferred Stock, Shares Authorized																																20,000,000

Note 3 - Stockholders' Defici57

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)				31,349	17,944	15,430
Average Exercise Price Outstanding (in dollars per share)				$ 133.25	$ 187.75	$ 168.75
Number of Shares Issued (in shares)				100,837	14,171	3,028
Average Exercise Price Issued (in dollars per share)				$ 3.329	$ 69	$ 203
Number of Shares Expired (in shares)				(22,377)	(766)	(316)
Average Exercise Price Expired (in dollars per share)				$ 122.132	$ 293.25	$ 589.50
Number of Shares Exercised (in shares)				(1,312)		(198)
Average Exercise Price Exercised (in dollars per share)				$ 65.75		$ 44
Number of Shares Exercised (in shares)
Number of Shares Outstanding (in shares)				108,498	31,349	17,944
Average Exercise Price Outstanding (in dollars per share)				$ 15.652	$ 133.25	$ 187.75
Number of Shares Cancelled (in shares)					(766)
Average Exercise Price Cancelled (in dollars per share)					$ 293.25
Warrant [Member]
Number of Shares Outstanding (in shares)				323,098	20,028	18,477
Average Exercise Price Outstanding (in dollars per share)				$ 128.50	$ 198.75	$ 262.50
Number of Shares Issued (in shares)				730,882	303,269	6,455
Average Exercise Price Issued (in dollars per share)				$ 1.44	$ 123.75	$ 95.25
Number of Shares Expired (in shares)					(79)	(3,275)
Average Exercise Price Expired (in dollars per share)					$ 283.50	$ 338.50
Number of Shares Exercised (in shares)				(939,879)	(120)	(1,629)
Average Exercise Price Exercised (in dollars per share)					$ 123.75	$ 209.50
Number of Shares Outstanding (in shares)					323,098	20,028
Average Exercise Price Outstanding (in dollars per share)				$ 369.06	$ 128.50	$ 198.75
Number of Shares Cancelled (in shares)					(79)
Number of Shares Outstanding (in shares)				31,349
Number of Shares Exercised (in shares)	(178)	(149)	(178)
Average Exercise Price Exercised (in dollars per share)				$ 65.75
Number of Shares Outstanding (in shares)				108,498	31,349
Average Exercise Price Outstanding (in dollars per share)

Note 3 - Stockholders' Defici58

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Mar. 31, 2014
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 65.75
Shares, options (in shares)	293	10,019
Weighted average remaining life, options	9 years 328 days	9 years 295 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 73.50
Shares, options (in shares)	37,152	1,225
Weighted average remaining life, options	9 years 324 days	10 years 3 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 77.50
Shares, options (in shares)	44,000	2,387
Weighted average remaining life, options	9 years 277 days	9 years 182 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 80.25
Shares, options (in shares)	3,636	250
Weighted average remaining life, options	10 years	9 years 277 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 86.25
Shares, options (in shares)	7,147	289
Weighted average remaining life, options	9 years 354 days	9 years 91 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 121.88
Shares, options (in shares)	3,529	6
Weighted average remaining life, options	9 years 182 days	7 years 73 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 131.25
Shares, options (in shares)	3,902	82
Weighted average remaining life, options	9 years 343 days	6 years 251 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 140.63
Shares, options (in shares)	342	7,679
Weighted average remaining life, options	9 years 21 days	7 years 76 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 148.13
Shares, options (in shares)	1,157	929
Weighted average remaining life, options	9 years 94 days	7 years 80 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 150
Shares, options (in shares)	2,323	4,959
Weighted average remaining life, options	8 years 273 days	6 years 229 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 162.50
Shares, options (in shares)	187	153
Weighted average remaining life, options	9 years 3 days	9 years 3 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 206.25
Shares, options (in shares)	232	145
Weighted average remaining life, options	8 years 182 days	8 years 277 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 121.875	$ 248.44
Shares, options (in shares)	5	120
Weighted average remaining life, options	6 years 164 days	7 years 197 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 262.50
Shares, options (in shares)	81	130
Weighted average remaining life, options	5 years 343 days	7 years 197 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 148.125	$ 281.25
Shares, options (in shares)	928	546
Weighted average remaining life, options	6 years 171 days	7 years 32 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 150	$ 318.75
Shares, options (in shares)	1,760	3
Weighted average remaining life, options	5 years 321 days	7 years 131 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50	$ 346.88
Shares, options (in shares)	123	87
Weighted average remaining life, options	8 years 94 days	8 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 206.25	$ 431.25
Shares, options (in shares)	121	1,610
Weighted average remaining life, options	8 years 3 days	8 years 69 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 248.4375	$ 468.75
Shares, options (in shares)	121	134
Weighted average remaining life, options	6 years 288 days	8 years 54 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 262.50	$ 506.25
Shares, options (in shares)	130	198
Weighted average remaining life, options	6 years 288 days	8 years 3 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 281.25	$ 543.75
Shares, options (in shares)	529	54
Weighted average remaining life, options	6 years 109 days	7 years 281 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 318.75	$ 596.25
Shares, options (in shares)	3	51
Weighted average remaining life, options	6 years 219 days	7 years 273 days
Warrant One [Member]
Warrant exercise price (in dollars per share)	$ 93.75	$ 123.75
Shares, warrants (in shares)	2,255	303,081
Weighted average remaining life, warrants	1 year 164 days	4 years 244 days
Warrant Two [Member]
Warrant exercise price (in dollars per share)	$ 123.75	$ 150
Shares, warrants (in shares)	94,084	4,114
Weighted average remaining life, warrants	3 years 335 days	2 years 73 days
Warrant Three [Member]
Warrant exercise price (in dollars per share)	$ 150	$ 225
Shares, warrants (in shares)	4,114	107
Weighted average remaining life, warrants	1 year 164 days	2 years 25 days
Warrant Four [Member]
Warrant exercise price (in dollars per share)	$ 225	$ 243.75
Shares, warrants (in shares)	107	2,529
Weighted average remaining life, warrants	1 year 116 days	3 years 215 days
Warrant Five [Member]
Warrant exercise price (in dollars per share)	$ 243.75	$ 281.25
Shares, warrants (in shares)	2,529	8,152
Weighted average remaining life, warrants	2 years 306 days	2 years 7 days
Warrant Six [Member]
Warrant exercise price (in dollars per share)	$ 281.25	$ 309.38
Shares, warrants (in shares)	5,897	2,850
Weighted average remaining life, warrants	1 year 73 days	3 years 222 days
Warrant Seven [Member]
Warrant exercise price (in dollars per share)	$ 309.375	$ 309.50
Shares, warrants (in shares)	2,850	222
Weighted average remaining life, warrants	2 years 313 days	3 years 310 days
Warrant Eight [Member]
Warrant exercise price (in dollars per share)	$ 309.50	$ 337.50
Shares, warrants (in shares)	222	178
Weighted average remaining life, warrants	3 years 36 days	2 years 171 days
Warrant Nine [Member]
Warrant exercise price (in dollars per share)	$ 337.50	$ 371.25
Shares, warrants (in shares)	178	944
Weighted average remaining life, warrants	1 year 262 days	2 years 149 days
Warrant Ten [Member]
Warrant exercise price (in dollars per share)	$ 371.25	$ 506.25
Shares, warrants (in shares)	944	59
Weighted average remaining life, warrants	1 year 240 days	3 years 47 days
Warrant Eleven [Member]
Warrant exercise price (in dollars per share)	$ 506.25	$ 609.38
Shares, warrants (in shares)	59	861
Weighted average remaining life, warrants	2 years 138 days	3 years 36 days
Range of exercise prices, options (in dollars per share)
Shares, options (in shares)	108,498	31,349
Weighted average remaining life, options
Warrant exercise price (in dollars per share)			$ 281.25
Shares, warrants (in shares)	114,102	323,098
Weighted average remaining life, warrants

Note 3 - Stockholders' Equity59

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Stock Options 2011 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0
Stock Options 2011 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 281.25
Stock Options 2011 [Member]
Shares, options (in shares)	173	467
Price, options (in dollars per share)		$ 18.75
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25	131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	5,041
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 121.88	$ 121.88
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2013 [Member]
Shares, options (in shares)	1,612	9,310
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 468.75	$ 468.75
Stock Options 2014 [Member]
Shares, options (in shares)	969	2,361
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,240	14,170
Warrants 2012 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)		$ 281.25
Warrants 2012 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)		$ 375
Warrants 2012 [Member]
Shares, warrants (in shares)	2,792	2,792
Warrant exercise price (in dollars per share)	$ 281.25
Warrants 2013 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	93.75	$ 150
Warrants 2013 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 371.25	$ 371.25
Warrants 2013 [Member]
Shares, warrants (in shares)	10,703	10,703
Warrants 2014 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	$ 243.75	$ 309.38
Warrants 2014 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 609.38	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2015 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 243.75
Warrants 2015 [Member]
Shares, warrants (in shares)	94,152	303,148
Warrant exercise price (in dollars per share)		$ 123.75
Minimum [Member]
Price, options (in dollars per share)	$ 0	6.8745	$ 80.015
Warrant exercise price (in dollars per share)	0	123.75
Maximum [Member]
Price, options (in dollars per share)	596.25	139.2386	$ 347.9864
Warrant exercise price (in dollars per share)	$ 609.38	$ 609.38
Shares, options (in shares)	108,498	31,349
Shares, warrants (in shares)	114,102	323,098
Warrant exercise price (in dollars per share)				$ 281.25

Note 4 - Short-term Notes Pay60

Note 4 - Short-term Notes Payable (Details Textual) - USD ($)	Aug. 31, 2015	May 31, 2015	May 30, 2015	Mar. 31, 2016	Sep. 30, 2014	Dec. 31, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 09, 2014	Jul. 31, 2014	Jun. 30, 2014	Feb. 28, 2014	Jan. 31, 2014
The 2014 Convertible Notes [Member] | SOK Partners LLC [Member]
Debt Instrument, Face Amount					$ 122,196
Proceeds from Convertible Debt					$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					218
The 2014 Convertible Notes [Member]
Debt Instrument, Face Amount					$ 1,800,000
Debt Instrument Reduced Face Amount					1,600,000				$ 1,603,260
Proceeds from Convertible Debt					$ 1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									2,851
Percentage Reduction to Debt Instrument Face Amount									11.00%
Percentage Reduction to Number of Warrants									11.00%
The 2015 Convertible Notes [Member]
Debt Instrument, Face Amount		$ 275,000	$ 275,000
Proceeds from Convertible Debt		$ 250,000	$ 250,000
Class of Warrant or Right Issued During Period		0	0
The Convertible Notes [Member]
Debt Instrument, Face Amount							$ 933,073
Debt Conversion, Converted Instrument, Amount							$ 927,663	$ 927,663
Debt Instrument, Redemption Price, Percentage				140.00%		140.00%
Debt Instrument Redemption Principal Amount	$ 933,074
Debt Instrument Redemption Premium Percentage	40.00%
Debt Instrument Redemption Price	$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates	$ 167,031
Short-term Debt						$ 0		$ 0
SOK Partners LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									194		218
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												862	862
Percentage Reduction to Number of Warrants					11.00%				11.00%	11.00%

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	222,600	343,554	354.447	37,972
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			75,921

Note 5 - Loss Per Share - Share

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2016		Sep. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2015		Dec. 31, 2014
Net loss	$ (1,055,593)		$ (1,116,402)		$ (5,793,242)		$ (2,527,524)		$ (4,790,530)		$ (6,833,568)
Weighted average common shares outstanding-basic (in shares)	3,320,139		157,445		2,250,315		137,428		155,234		119,619
Effect of dilutive stock options, warrants and preferred stock (1) (in shares)		[1]		[1]		[1]		[1]		[2]		[2]
Weighted average common shares outstanding-diluted (in shares)									155,234		119,619
Loss per common share - basic and diluted (in dollars per share)	$ (0.32)		$ (7.09)		$ (2.57)		$ (18.39)		$ (30.86)		$ (57.13)
[1]	The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2016	Dec. 31, 2014
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 24,700,000	$ 29,200,000	$ 18,700,000
Operating Loss Carryforwards, Valuation Allowance	9,600,000	10,100,000	8,100,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	13,400,000	15,000,000	12,400,000
Operating Loss Carryforwards, Valuation Allowance	1,100,000	$ 0.30	$ 1,000,000
Income Tax Expense (Benefit)	$ 0
Valuation Allowance Percentage	100.00%

Note 6 - Income Taxes - Compone

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Operating Loss	$ 10,271,000	$ 10,338,000	$ 7,919,000
Other	166,000	359,000	1,150,000
Total Deferred Tax Asset	10,437,000	10,697,000	9,069,000
Less Valuation Allowance	10,437,000	10,697,000	9,069,000
Net Deferred Income Taxes	$ 0	$ 0	$ 0

Note 7 - Rent Obligation (Detai

Note 7 - Rent Obligation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation			3 years		3 years
Lessee Leasing Arrangements Operating Leases Extension Term			5 years		5 years
Operating Leases, Rent Expense	$ 16,356	$ 15,900	$ 50,106	$ 50,156	$ 66,345	$ 64,753
Lessor Leasing Arrangements, Operating Leases, Term of Contract					3 years

Note 7 - Rent Obligation - Rent

Note 7 - Rent Obligation - Rent Obligation (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
2,016	$ 9,500	$ 38,000
2,017	39,000	39,000
2,018	$ 3,600	$ 3,000

Note 8 - Liability for Equity67

Note 8 - Liability for Equity-linked Financial Instruments (Details Textual) - USD ($)	9 Months Ended	12 Months Ended			72 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2014	Dec. 31, 2010
Decrease in Equity Caused by Adoption of ASC 815 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification				$ 479,910
Decrease in Additional Paid in Capital Caused by Adoption of ASC 815 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification				486,564
Increase in Retained Earnings Caused by Adoption of ASC 815 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification				6,654
Increase in Liabilities Caused by Adoption of ASC 815 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification				$ 479,910
Derivative Liability			$ 0		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				2 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				63.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price				$ 862.50
Share Price	$ 4.125			$ 656.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.37%
Share Price Reduction				$ 937.50		$ 412.50

Note 8 - Liability for Equity68

Note 8 - Liability for Equity-linked Financial Instruments - Inputs to Black-Scholes Model (Details) - $ / shares	9 Months Ended	12 Months Ended			72 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2014
Minimum [Member]
Stock price (in dollars per share)			$ 93.75		$ 93.75
Exercise price (in dollars per share)			$ 18.75		$ 18.75
Expected life (years)		5 years	5 years		2 years
Risk-free interest rate	1.46%	1.63%	1.44%		0.13%
Maximum [Member]
Stock price (in dollars per share)			$ 937.50		$ 937.50
Exercise price (in dollars per share)			$ 609.50		$ 609.50
Expected life (years)	10 years	10 years	10 years		6 years 182 days
Risk-free interest rate	1.78%	2.35%	2.75%		2.97%
Stock price (in dollars per share)	$ 4.125			$ 656.25
Exercise price (in dollars per share)				$ 862.50
Expected life (years)				2 years 182 days
Expected volatility				63.00%	59.00%
Assumed dividend rate	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate				1.37%

Note 8 - Liabiltiy for Equity-l

Note 8 - Liabiltiy for Equity-linked Financial Instruments - Original Valuations, Annual Gain (Loss) and End of Year Valuations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
January 1, 2009 Adoption [Member | Gain (Loss) 2009 [Member]
Gain (Loss)						$ (390,368)
January 1, 2009 Adoption [Member | Value at 2009 [Member]
Gain (Loss)						870,278
January 1, 2009 Adoption [Member | Gain (Loss) 2010 [Member]
Gain (Loss)					$ 868,772
January 1, 2009 Adoption [Member | Value at 2010 [Member]
Gain (Loss)					1,506
January 1, 2009 Adoption [Member | Gain (Loss) 2011 [Member]
Gain (Loss)				$ (88,290)
January 1, 2009 Adoption [Member | Value at 2011 [Member]
Gain (Loss)				89,796
January 1, 2009 Adoption [Member | Gain (Loss) 2012 [Member]
Gain (Loss)			$ (21,856)
January 1, 2009 Adoption [Member | Value at 2012 [Member]
Gain (Loss)			111,652
January 1, 2009 Adoption [Member | Gain (Loss) 2013 [Member]
Gain (Loss)		$ 100,053
January 1, 2009 Adoption [Member | Value at 2013 [Member]
Gain (Loss)		11,599
January 1, 2009 Adoption [Member | Gain (Loss) 2014 [Member]
Gain (Loss)	$ 11,599
January 1, 2009 Adoption [Member | Value at 2014 [Member]
Gain (Loss)
January 1, 2009 Adoption [Member
Value							$ 479,910
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)						20,847
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2009 [Member]
Gain (Loss)						149,007
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					147,403
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2010 [Member]
Gain (Loss)					1,604
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(4,689)
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2011 [Member]
Gain (Loss)				6,293
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			6,293
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2012 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2009 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2009 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2009 [Member]
Value							169,854
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)						(738)
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2009 [Member]
Gain (Loss)						40,481
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					40,419
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2010 [Member]
Gain (Loss)					62
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(1,562)
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2011 [Member]
Gain (Loss)				1,624
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			910
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2012 [Member]
Gain (Loss)			714
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)		714
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2009 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2009 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2009 [Member]
Value							39,743
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)						617
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2009 [Member]
Gain (Loss)						12,081
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					12,053
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2010 [Member]
Gain (Loss)					28
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(724)
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2011 [Member]
Gain (Loss)				752
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			415
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2012 [Member]
Gain (Loss)			337
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)		337
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 12/31/2009 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 12/31/2009 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 12/31/2009 [Member]
Value							12,698
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2009 [Member]
Gain (Loss)						1,071,847
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2010 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2011 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2012 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in 2009 and January 1, 2009 Adoption [Member]
Value							702,205
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					25,014
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2010 [Member]
Gain (Loss)					539
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(5,570)
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2011 [Member]
Gain (Loss)				6,109
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			3,701
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2012 [Member]
Gain (Loss)			2,408
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)		2,408
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 3/31/2010 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 3/31/2010 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 3/31/2010 [Member]
Value							25,553
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					30,740
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2010 [Member]
Gain (Loss)					592
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(6,122)
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2011 [Member]
Gain (Loss)				6,714
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			6,083
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2012 [Member]
Gain (Loss)			631
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)		631
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2010 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2010 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 6/30/2010 [Member]
Value							31,332
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2009 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2010 [Member]
Gain (Loss)					20,891
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2010 [Member]
Gain (Loss)					10,615
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2011 [Member]
Gain (Loss)				(44,160)
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2011 [Member]
Gain (Loss)				54,775
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2012 [Member]
Gain (Loss)			1,338
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2012 [Member]
Gain (Loss)			53,437
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2013 [Member]
Gain (Loss)		53,437
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2013 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2010 [Member] | Gain (Loss) 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2010 [Member] | Value at 2014 [Member]
Gain (Loss)
Issued in Quarter Ended 9/30/2010 [Member]
Value							31,506
Gain (Loss) 2009 [Member]
Gain (Loss)						(369,642)
Value at 2009 [Member]
Gain (Loss)						$ 1,071,847
Gain (Loss) 2010 [Member]
Gain (Loss)					1,145,292
Value at 2010 [Member]
Gain (Loss)					$ 14,946
Gain (Loss) 2011 [Member]
Gain (Loss)				(151,117)
Value at 2011 [Member]
Gain (Loss)				$ 166,063
Gain (Loss) 2012 [Member]
Gain (Loss)			(3,116)
Value at 2012 [Member]
Gain (Loss)			$ 169,179
Gain (Loss) 2013 [Member]
Gain (Loss)		157,580
Value at 2013 [Member]
Gain (Loss)		$ 11,599
Gain (Loss) 2014 [Member]
Gain (Loss)	11,599
Value at 2014 [Member]
Gain (Loss)
Total							$ 790,596

Note 9 - Related Party Transc70

Note 9 - Related Party Transcations (Details Textual) - USD ($)	Aug. 31, 2015	Feb. 04, 2014	Aug. 31, 2015	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Oct. 24, 2016	Jul. 31, 2014	Feb. 28, 2014	Jan. 31, 2014
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues		19,231
Stock Issued During Period, Value, New Issues		$ 25,000
Chief Executive Officer [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3
Chief Executive Officer [Member] | Stock Conversion from Series A Convertible Stock to Exchange Units [Member]
Conversion of Stock, Shares Converted	250
Conversion of Stock, Shares Issued	2,778
SOK Partners LLC [Member] | The Convertible Notes [Member]
Debt Instrument, Redemption Price, Percentage			140.00%
Repayments of Related Party Debt			$ 163,000
SOK Partners LLC [Member]
Ownership Percentage								10.00%
Common Stock [Member]
Stock Issued During Period, Shares, New Issues					66,667		3,804,860
Stock Issued During Period, Value, New Issues					$ 667
Stock Issued During Period, Shares, New Issues	1,666,667			548
Stock Issued During Period, Value, New Issues					$ 13,060,880	$ 2,055,001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									862	862

Note 10 - Retirement Savings 71

Note 10 - Retirement Savings Plans (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100.00%		100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			4.00%		4.00%	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 7,401	$ 7,021	$ 28,196	$ 21,735	$ 39,916	$ 37,730

Note 11 - Supplemental Cash F72

Note 11 - Supplemental Cash Flow Data (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Interest Paid	$ 3	$ 226,960	$ 3	$ 237,121	$ 246,620	$ 47,111

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual)	1 Months Ended
	Jan. 31, 2016shares
Subsequent Event [Member]
Units Exchanged During Period	1,895,010

Note 1 - Summary of Significa74

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Oct. 27, 2016	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Oct. 04, 2016$ / shares	Nov. 30, 2014$ / shares
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share | $ / shares										$ 0.01
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues								$ 2,055,000	$ 2,055,000
IPO [Member]
Stock Issued During Period, Value, New Issues								$ 13,555,003	$ 13,555,003
Earliest Tax Year [Member]
Open Tax Year				2,012		2,012
Common Stock, Shares, Outstanding | shares		3,404,860		3,404,860		208,259	123,711	208,259	3,404,860
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01		$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Stockholders' Equity, Period Increase (Decrease)				$ 22,325,091				$ 22,732,961
Stock Issued During Period, Value, New Issues						$ 13,060,880	$ 2,055,001
Debt Instrument, Increase (Decrease), Net								5,685,000	$ 5,685,000
Advertising Expense		$ 10,343	$ 500	57,004	$ 1,917	8,220	19,394
Research and Development Expense		79,936	58,792	302,330	179,739	261,000	$ 394,000
Amortization of Intangible Assets		2,515	1,632	6,225	4,520
Cash, Uninsured Amount		454,369		454,369		4,621,764		$ 4,621,764	$ 454,369
Product Warranty Expense		$ 2,102	$ 12,084	$ 33,083	$ 39,688	$ 56,201
Number of Operating Segments				1		1

Note 1 - Summary of Significa75

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Finished goods	$ 72,540	$ 30,237	$ 88,362
Raw materials	157,044	162,623	237,556
Work-In-Process	59,665	38,880	41,449
Total	$ 289,249	$ 231,740	$ 367,367

Note 1 - Summary of Significa76

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Office Equipment [Member] | Minimum [Member]
Property Plant and Equipment	3 years	3 years
Office Equipment [Member] | Maximum [Member]
Property Plant and Equipment	7 years	7 years
Leasehold Improvements [Member]
Property Plant and Equipment	5 years	5 years
Manufacturing Tooling [Member] | Minimum [Member]
Property Plant and Equipment	3 years	3 years
Manufacturing Tooling [Member] | Maximum [Member]
Property Plant and Equipment	7 years	7 years
Demo Equipment [Member]
Property Plant and Equipment	3 years	3 years

Note 1 - Summary of Significa77

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Office Equipment [Member]
Property, Plant, and Equipment Gross	$ 164,319	$ 153,553	$ 123,708
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	25,635	23,874	23,874
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	101,104	97,288	97,288
Demo Equipment [Member]
Property, Plant, and Equipment Gross	17,702	8,962	30,576
Property, Plant, and Equipment Gross	308,760	283,677	275,446
Less: Accumulated Depreciation	197,850	144,079	78,967
Total Fixed Assets, Net	$ 110,910	$ 139,598	$ 196,479

Note 2 - Development Stage Op78

Note 2 - Development Stage Operations (Details Textual) - $ / shares	Aug. 31, 2015	Nov. 30, 2014	Dec. 31, 2015	Oct. 24, 2016	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2009
Common Stock [Member] | Maximum [Member]
Share Price				$ 3,131.25
Common Stock [Member]
Stock Issued During Period, Shares, New Issues			66,667	3,804,860
Share Price			$ 3,131.25
Maximum [Member]
Share Price						$ 937.50
Stock Issued During Period, Shares, New Issues	1,666,667	548
Share Price					$ 4.125		$ 656.25

Note 3 - Stockholders' Defici79

Note 3 - Stockholders' Deficit, Stock Options and Warrants (Details Textual)	Oct. 04, 2016$ / sharesshares	Jul. 01, 2016$ / sharesshares	Jun. 13, 2016shares	Mar. 31, 2016shares	Mar. 11, 2016$ / sharesshares	Aug. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares	Sep. 30, 2014$ / sharesshares	Sep. 14, 2014	Sep. 09, 2014$ / sharesshares	Jun. 30, 2014$ / sharesshares	Mar. 31, 2014$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Jun. 30, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Jan. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares	Nov. 30, 2014$ / sharesshares	Sep. 30, 2014$ / sharesshares	Aug. 31, 2014$ / sharesshares	Jun. 30, 2014$ / sharesshares	Mar. 31, 2014$ / sharesshares	Jan. 31, 2014USD ($)$ / sharesshares	Jul. 06, 2016shares	Mar. 31, 2014$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2009$ / shares	Dec. 31, 2014$ / sharesshares	Oct. 24, 2016$ / sharesshares	Sep. 16, 2016shares	Aug. 31, 2016shares	Apr. 21, 2016shares	Mar. 25, 2016$ / sharesshares	Jul. 24, 2015shares	Jul. 31, 2014$ / sharesshares	Feb. 28, 2014$ / sharesshares
Maximum [Member] | Common Stock [Member]
Share Price | $ / shares																																		$ 3,131.25
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																												3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																												10 years
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $						$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																												$ 609.38		$ 609.38
Share Price | $ / shares									$ 937.50										$ 937.50												$ 937.50		$ 937.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																												1.78%		2.35%	2.75%		2.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																												10 years		10 years	10 years		6 years 182 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																												$ 596.25		$ 139.2386	$ 347.9864
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																												$ 3.7195		139.24
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																												3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																												$ 0		$ 123.75
Share Price | $ / shares									93.75										93.75												$ 93.75		$ 93.75
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																												1.46%		1.63%	1.44%		0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																														5 years	5 years		2 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																												$ 0		$ 6.8745	$ 80.015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																												1.6329		6.88
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						75,800
Exchange Units [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						1,895,010
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						3,391
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						7,580,040
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued						228,343
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage						5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase						83,333
Unit Purchase Option Exercise Price, Percentage						125.00%
Unit Purchase Option Exercise Price | $ / shares						$ 11.25
Unit Purchase Option, Exercised						135,995
Exchange Units [Member]
Unit Purchase Option Units Issued						228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities						1,895,010
Employee Stock Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares																												$ 65.75			$ 44
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																												1,312			198
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																												100,837		14,171	3,028
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																												$ 3.329		$ 69	$ 203
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																												1 year 180 days
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period Shares Warrants Exercised																												628,237
Common Stock [Member] | Former CEO [Member]
Stock Issued During Period, Shares, New Issues																												20,000
Stock Issued During Period, Value, New Issues | $																												$ 200
Common Stock [Member]
Stock Issued During Period, Shares, New Issues																														66,667				3,804,860
Share Price | $ / shares																														$ 3,131.25
Stock Issued During Period Shares Warrants Exercised																												2,318,663		120
Stock Issued During Period, Value, Stock Options Exercised | $																												$ 13
Stock Issued During Period, Value, New Issues | $																														$ 667
Stock Issued During Period Shares Preferred Stock Conversion																												66,396		9,134
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																												1,312
Warrant [Member]
Cashless Exercise of Common Stock Warrants, Total																											618
Series B Convertible Preferred Stock [Member] | Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Preferred Stock Included in Each Unit						1
Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues															20,550
Beneficial Ownership Limitation Percentage						4.99%
Preferred Stock Par Value | $ / shares															$ 0.01
Preferred Stock Stated Value | $ / shares															$ 100
Stock Issued During Period, Value, New Issues | $															$ 2,055,000
Preferred Stock, Par or Stated Value Per Share | $ / shares									$ 0.01										$ 0.01									$ 0.01		$ 0.01	$ 0.01		$ 0.01
Preferred Stock, Shares Authorized									10,000,000										10,000,000									20,000,000		20,000,000	10,000,000		10,000,000
Preferred Stock, Shares Outstanding									0										0									79,246		1,895,010	0		0
Convertible Preferred Stock, Shares Issued upon Conversion						1
Series A Convertible Preferred Stock [Member] | Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Warrants Included in Each Unit						4
Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues															20,550
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																									$ 609.50
Preferred Stock Par Value | $ / shares															$ 0.01
Preferred Stock Stated Value | $ / shares									$ 100						$ 100				$ 100											$ 100	$ 100		$ 100
Stock Issued During Period, Value, New Issues | $															$ 2,055,000
Preferred Stock, Par or Stated Value Per Share | $ / shares									$ 0.01										$ 0.01											$ 0.01	$ 0.01		$ 0.01
Preferred Stock, Shares Authorized									10,000,000										10,000,000											10,000,000	10,000,000		10,000,000
Preferred Stock, Shares Outstanding									20,550										20,550											0	20,550		20,550			0
Series A Warrants [Member] | Corporate Stock Transfer Inc. [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member] | Subsequent Event [Member]
Stock Issued During Period Shares Warrants Exercised					1,685,229
Series A Warrants [Member] | Corporate Stock Transfer Inc. [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period Shares Warrants Exercised																												564
Series A Warrants [Member] | Corporate Stock Transfer Inc. [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					0.4
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares					$ 108.115
Class of Warrant or Right Exercised During Period					3,390,935
Stock Issued During Period Shares Warrants Exercised					1,362,147
Class of Warrant or Right, Outstanding					4,189,105
Series A Warrants [Member] | Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Warrants Included in Each Unit						4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1																						0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 4.95
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise						2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares					$ 0.43	$ 10.75
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares																												$ 108.115
Class of Warrant or Right Exercised During Period																												6,141,115
Stock Issued During Period Shares Warrants Exercised																												2,318,663
Class of Warrant or Right, Outstanding						35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares						$ 123.75
Beneficial Ownership Limitation Percentage						4.99%
Class of Warrant or Right Period Over Which Additional Adjustments to Price and Number of Shares May Be Made						3 years
Series A Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				0.04
Stock to be Issued for Exchange Offer, Shares, Maximum																																						3,157,186
Cashless Exercise of Common Stock Warrants, Total				0.4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																					1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																																						$ 0.01
Series B Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right Exercised During Period																										1,251,510
Stock Issued During Period Shares Warrants Exercised																										503,034
Cashless Exercise of Common Stock Warrants, Total				10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																					18,059,671
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit						1
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount | $						$ 933,074
Debt Instrument Redemption Premium Percentage						40.00%
Debt Instrument Redemption Price | $						$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates | $						$ 167,031
Chief Executive Officer [Member]
Stock Issued During Period, Value, Stock Options Exercised | $																									$ 174
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares																									$ 31.25
Dr.Samuel Herschkowitz [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																									$ 506.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																									60
Two Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																																								$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																								1,160
Purchasers [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities							125	125	63							125	125	125	63		63
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																						$ 609.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																						2,462
Preferred Stock, Dividend Rate, Percentage							6.00%	6.00%	6.00%	6.00%						6.00%	6.00%		6.00%		6.00%
Preferred Stock Conversion Price Per Share | $ / shares										$ 487.50								$ 487.50	$ 487.50		$ 487.50
Stock Issued During Period Shares Preferred Stock Conversion										63
Number of Preferred Stock Share holders							16	16	16	16						16	16	16	16		16										16		16
Maximum Number of Days Not Listed on Stock Market																						180 days
Preferred Stock, Par or Stated Value Per Share | $ / shares									$ 487.50										$ 487.50												$ 487.50		$ 487.50
Conversion of Stock Price Per Share | $ / shares							$ 243.75	$ 243.75								$ 243.75	$ 243.75	$ 243.75
Four Lenders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares										$ 309.50											$ 309.50	$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										1,498											1,498	1,498
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares		$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		40,000
Number of Equal Installments Options are Expected to Vest		6
Former CEO [Member]
Shares Issued, Price Per Share | $ / shares																												$ 4.50
Stock Issued During Period, Value, New Issues | $																												$ 90,351
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period			22,085
SOK Partners LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 309.50	$ 309.50										$ 309.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												194	218										218
Percentage of Reduction to Warrant Agreement											11.00%	11.00%
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	400,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01
Share Price | $ / shares					$ 4.50
Stock Issued During Period, Shares, New Issues						1,666,667														548
Shares Issued, Price Per Share | $ / shares						$ 9
Underwriter Price | $ / shares						8.28
Underwriting Discount | $ / shares						$ 0.72
Underwriting Commission						8.00%
Proceeds from Issuance or Sale of Equity | $						$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period						45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted						250,000
Option Granted to Underwriter to Purchase Additional Units Additional Units Purchased						0
Underwriting Agreement Non-accountable Expense Allowance Percentage						1.00%
Common Stock, Par or Stated Value Per Share | $ / shares									$ 0.01										$ 0.01	$ 0.01								$ 0.01		$ 0.01	$ 0.01		$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 281.25										$ 281.25			$ 281.25
Share Price | $ / shares																												$ 4.125				$ 656.25
Class of Warrant or Right, Outstanding																												114,102		323,098
Cashless Exercise of Common Stock Warrants, Total														134										134
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									862																862
Stock Issued During Period, Value, Stock Options Exercised | $																												$ 86,253
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares																												$ 65.75
Stock Issued During Period, Value, New Issues | $																														$ 13,060,880	$ 2,055,001
Preferred Stock, Dividend Rate, Percentage													6.00%	6.00%
Preferred Stock Conversion Price Per Share | $ / shares													$ 487.50	$ 487.50
Stock Issued During Period Shares Preferred Stock Conversion													63	39
Number of Preferred Stock Share holders													16	16									16	16			16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period														178									149	178
Percentage Reduction to Number of Warrants										11.00%		11.00%									11.00%																			11.00%
Preferred Stock, Par or Stated Value Per Share | $ / shares													$ 487.50										$ 487.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																																1.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																												0.00%		0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																														59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																												66.00%		66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																																2 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																												64,542		31,229
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares																												$ 23.46		$ 132.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																												9 years 208 days		8 years 62 days
Allocated Share-based Compensation Expense | $																												$ 1,393,862	$ 320,334	$ 871,877	$ 723,367
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $																												$ 132,675		$ 32,682
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																														60 days
Common Stock, Shares Authorized									4,000,000										4,000,000									8,000,000		8,000,000	4,000,000		4,000,000		8,000,000				4,000,000
Preferred Stock, Shares Authorized																																							20,000,000

Note 3 - Stockholders' Defici80

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)				31,349	17,944	15,430
Average Exercise Price Outstanding (in dollars per share)				$ 133.25	$ 187.75	$ 168.75
Number of Shares Issued (in shares)				100,837	14,171	3,028
Average Exercise Price Issued (in dollars per share)				$ 3.329	$ 69	$ 203
Number of Shares Expired (in shares)				(22,377)	(766)	(316)
Average Exercise Price Expired (in dollars per share)				$ 122.132	$ 293.25	$ 589.50
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)				$ 65.75		$ 44
Number of Shares Outstanding (in shares)				108,498	31,349	17,944
Average Exercise Price Outstanding (in dollars per share)				$ 15.652	$ 133.25	$ 187.75
Number of Shares Exercised (in shares)				(1,312)		(198)
Warrant [Member]
Number of Shares Outstanding (in shares)				323,099	20,029
Average Exercise Price Outstanding (in dollars per share)				$ 128.50	$ 198.75	$ 262.50
Number of Shares Issued (in shares)				730,882	303,269	6,455
Average Exercise Price Issued (in dollars per share)				$ 1.44	$ 123.75	$ 95.25
Number of Shares Expired (in shares)					(79)	(3,275)
Average Exercise Price Expired (in dollars per share)					$ 283.50	$ 338.50
Number of Shares Exercised (in shares)				(939,879)	(120)	(1,629)
Average Exercise Price Exercised (in dollars per share)					$ 123.75	$ 209.50
Number of Shares Outstanding (in shares)				114,102	323,099	20,029
Average Exercise Price Outstanding (in dollars per share)				$ 369.06	$ 128.50	$ 198.75
Number of Shares Outstanding (in shares)				31,349
Average Exercise Price Exercised (in dollars per share)				$ 65.75
Number of Shares Outstanding (in shares)				108,498	31,349
Average Exercise Price Outstanding (in dollars per share)
Number of Shares Exercised (in shares)	(178)	(149)	(178)

Note 3 - Stockholders' Defici81

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Mar. 31, 2014
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 65.75
Shares, options (in shares)	293	10,019
Weighted average remaining life, options	9 years 328 days	9 years 295 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 73.50
Shares, options (in shares)	37,152	1,225
Weighted average remaining life, options	9 years 324 days	10 years 3 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 77.50
Shares, options (in shares)	44,000	2,387
Weighted average remaining life, options	9 years 277 days	9 years 182 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 80.25
Shares, options (in shares)	3,636	250
Weighted average remaining life, options	10 years	9 years 277 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 86.25
Shares, options (in shares)	7,147	289
Weighted average remaining life, options	9 years 354 days	9 years 91 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 121.88
Shares, options (in shares)	3,529	6
Weighted average remaining life, options	9 years 182 days	7 years 73 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 131.25
Shares, options (in shares)	3,902	82
Weighted average remaining life, options	9 years 343 days	6 years 251 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 140.63
Shares, options (in shares)	342	7,679
Weighted average remaining life, options	9 years 21 days	7 years 76 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 148.13
Shares, options (in shares)	1,157	929
Weighted average remaining life, options	9 years 94 days	7 years 80 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 150
Shares, options (in shares)	2,323	4,959
Weighted average remaining life, options	8 years 273 days	6 years 229 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 162.50
Shares, options (in shares)	187	153
Weighted average remaining life, options	9 years 3 days	9 years 3 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 206.25
Shares, options (in shares)	232	145
Weighted average remaining life, options	8 years 182 days	8 years 277 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 121.875	$ 248.44
Shares, options (in shares)	5	120
Weighted average remaining life, options	6 years 164 days	7 years 197 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 262.50
Shares, options (in shares)	81	130
Weighted average remaining life, options	5 years 343 days	7 years 197 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 148.125	$ 281.25
Shares, options (in shares)	928	546
Weighted average remaining life, options	6 years 171 days	7 years 32 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 150	$ 318.75
Shares, options (in shares)	1,760	3
Weighted average remaining life, options	5 years 321 days	7 years 131 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50	$ 346.88
Shares, options (in shares)	123	87
Weighted average remaining life, options	8 years 94 days	8 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 206.25	$ 431.25
Shares, options (in shares)	121	1,610
Weighted average remaining life, options	8 years 3 days	8 years 69 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 248.4375	$ 468.75
Shares, options (in shares)	121	134
Weighted average remaining life, options	6 years 288 days	8 years 54 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 262.50	$ 506.25
Shares, options (in shares)	130	198
Weighted average remaining life, options	6 years 288 days	8 years 3 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 281.25	$ 543.75
Shares, options (in shares)	529	54
Weighted average remaining life, options	6 years 109 days	7 years 281 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 318.75	$ 596.25
Shares, options (in shares)	3	51
Weighted average remaining life, options	6 years 219 days	7 years 273 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share)	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options	7 years 182 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share)	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options	7 years 160 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share)	$ 468.75
Shares, options (in shares)	133
Weighted average remaining life, options	7 years 146 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share)	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options	7 years 91 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 543.75
Shares, options (in shares)	53
Weighted average remaining life, options	7 years 7 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options	7 years
Warrant One [Member]
Warrant exercise price (in dollars per share)	$ 93.75	$ 123.75
Shares, warrants (in shares)	2,255	303,081
Weighted average remaining life, warrants	1 year 164 days	4 years 244 days
Warrant Two [Member]
Warrant exercise price (in dollars per share)	$ 123.75	$ 150
Shares, warrants (in shares)	94,084	4,114
Weighted average remaining life, warrants	3 years 335 days	2 years 73 days
Warrant Three [Member]
Warrant exercise price (in dollars per share)	$ 150	$ 225
Shares, warrants (in shares)	4,114	107
Weighted average remaining life, warrants	1 year 164 days	2 years 25 days
Warrant Four [Member]
Warrant exercise price (in dollars per share)	$ 225	$ 243.75
Shares, warrants (in shares)	107	2,529
Weighted average remaining life, warrants	1 year 116 days	3 years 215 days
Warrant Five [Member]
Warrant exercise price (in dollars per share)	$ 243.75	$ 281.25
Shares, warrants (in shares)	2,529	8,152
Weighted average remaining life, warrants	2 years 306 days	2 years 7 days
Warrant Six [Member]
Warrant exercise price (in dollars per share)	$ 281.25	$ 309.38
Shares, warrants (in shares)	5,897	2,850
Weighted average remaining life, warrants	1 year 73 days	3 years 222 days
Warrant Seven [Member]
Warrant exercise price (in dollars per share)	$ 309.375	$ 309.50
Shares, warrants (in shares)	2,850	222
Weighted average remaining life, warrants	2 years 313 days	3 years 310 days
Warrant Eight [Member]
Warrant exercise price (in dollars per share)	$ 309.50	$ 337.50
Shares, warrants (in shares)	222	178
Weighted average remaining life, warrants	3 years 36 days	2 years 171 days
Warrant Nine [Member]
Warrant exercise price (in dollars per share)	$ 337.50	$ 371.25
Shares, warrants (in shares)	178	944
Weighted average remaining life, warrants	1 year 262 days	2 years 149 days
Warrant Ten [Member]
Warrant exercise price (in dollars per share)	$ 371.25	$ 506.25
Shares, warrants (in shares)	944	59
Weighted average remaining life, warrants	1 year 240 days	3 years 47 days
Warrant Eleven [Member]
Warrant exercise price (in dollars per share)	$ 506.25	$ 609.38
Shares, warrants (in shares)	59	861
Weighted average remaining life, warrants	2 years 138 days	3 years 36 days
Warrant Twelve [Member]
Warrant exercise price (in dollars per share)	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants	2 years 124 days
Range of exercise prices, options (in dollars per share)
Shares, options (in shares)	108,498	31,349
Weighted average remaining life, options
Warrant exercise price (in dollars per share)			$ 281.25
Shares, warrants (in shares)	114,102	323,098
Weighted average remaining life, warrants

Note 3 - Stockholders' Defici82

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Stock Options 2011 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0
Stock Options 2011 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 281.25
Stock Options 2011 [Member]
Shares, options (in shares)	173	467
Price, options (in dollars per share)		$ 18.75
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25	131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	5,041
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 121.88	$ 121.88
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2013 [Member]
Shares, options (in shares)	1,612	9,310
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 468.75	$ 468.75
Stock Options 2014 [Member]
Shares, options (in shares)	969	2,361
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,240	14,170
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2016 [Member]
Shares, options (in shares)	99,661
Warrants 2012 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)		$ 281.25
Warrants 2012 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)		$ 375
Warrants 2012 [Member]
Shares, warrants (in shares)	2,792	2,792
Warrant exercise price (in dollars per share)	$ 281.25
Warrants 2013 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	93.75	$ 150
Warrants 2013 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 371.25	$ 371.25
Warrants 2013 [Member]
Shares, warrants (in shares)	10,703	10,703
Warrants 2014 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	$ 243.75	$ 309.38
Warrants 2014 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 609.38	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2015 [Member] | Minimum [Member]
Warrant exercise price (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercise price (in dollars per share)	$ 243.75
Warrants 2015 [Member]
Shares, warrants (in shares)	94,152	303,148
Warrant exercise price (in dollars per share)		$ 123.75
Minimum [Member]
Price, options (in dollars per share)	$ 0	6.8745	$ 80.015
Warrant exercise price (in dollars per share)	0	123.75
Maximum [Member]
Price, options (in dollars per share)	596.25	139.2386	$ 347.9864
Warrant exercise price (in dollars per share)	$ 609.38	$ 609.38
Shares, options (in shares)	108,498	31,349
Shares, warrants (in shares)	114,102	323,098
Warrant exercise price (in dollars per share)				$ 281.25

Note 4 - Short-term Notes Pay83

Note 4 - Short-term Notes Payable (Details Textual) - USD ($)	Aug. 31, 2015	May 31, 2015	May 30, 2015	Mar. 31, 2016	Sep. 30, 2014	Dec. 31, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 09, 2014	Jul. 31, 2014	Jun. 30, 2014	Feb. 28, 2014	Jan. 31, 2014
The 2015 Convertible Notes [Member]
Class of Warrant or Right Issued During Period		0	0
Debt Instrument, Face Amount		$ 275,000	$ 275,000
Proceeds from Convertible Debt		$ 250,000	$ 250,000
The Convertible Notes [Member]
Short-term Debt						$ 0		$ 0
Debt Instrument, Face Amount							$ 933,073
Debt Conversion, Converted Instrument, Amount							$ 927,663	$ 927,663
Debt Instrument, Redemption Price, Percentage				140.00%		140.00%
Debt Instrument Redemption Principal Amount	$ 933,074
Debt Instrument Redemption Premium Percentage	40.00%
Debt Instrument Redemption Price	$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates	$ 167,031
The 2014 Convertible Notes [Member] | SOK Partners LLC [Member]
Debt Instrument, Face Amount					$ 122,196
Proceeds from Convertible Debt					$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					218
The 2014 Convertible Notes [Member]
Debt Instrument, Face Amount					$ 1,800,000
Debt Instrument Reduced Face Amount					1,600,000				$ 1,603,260
Proceeds from Convertible Debt					$ 1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									2,851
Percentage Reduction to Debt Instrument Face Amount									11.00%
Percentage Reduction to Number of Warrants									11.00%
SOK Partners LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									194		218
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												862	862
Percentage Reduction to Number of Warrants					11.00%				11.00%	11.00%

Note 5 - Loss Per Share (Deta84

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	222,600	343,554	354.447	37,972

Note 5 - Loss Per Share - Sha85

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2016		Sep. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2015		Dec. 31, 2014
Net loss available in basic and diluted calculation	$ (1,055,593)		$ (1,116,402)		$ (5,793,242)		$ (2,527,524)		$ (4,790,530)		$ (6,833,568)
Unrealized gain (loss) from marketable securities	(1,299)				4,579
Comprehensive (loss)	$ (1,056,892)		$ (1,116,402)		$ (5,788,663)		$ (2,527,524)
Weighted average common shares outstanding-basic (in shares)	3,320,139		157,445		2,250,315		137,428		155,234		119,619
Effect of diluted stock options, warrants and preferred stock (1) (in shares)		[1]		[1]		[1]		[1]		[2]		[2]
Loss per common share-basic and diluted (in dollars per share)	$ (0.32)		$ (7.09)		$ (2.57)		$ (18.39)		$ (30.86)		$ (57.13)
[1]	The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
[2]	The number of shares underlying options and warrants outstanding as of September 30, 2016 and September 30, 2015 are 222,600 and 343,554 respectively. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Detail86

Note 6 - Income Taxes (Details Textual) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 29,200,000	$ 24,700,000	$ 18,700,000
Operating Loss Carryforwards, Valuation Allowance	10,100,000	9,600,000	8,100,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	15,000,000	13,400,000	12,400,000
Operating Loss Carryforwards, Valuation Allowance	$ 0.30	$ 1,100,000	$ 1,000,000

Note 6 - Income Taxes - Compo87

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Operating Loss	$ 10,271,000	$ 10,338,000	$ 7,919,000
Other	166,000	359,000	1,150,000
Total Deferred Tax Asset	10,437,000	10,697,000	9,069,000
Less Valuation Allowance	10,437,000	10,697,000	9,069,000
Net Deferred Income Taxes	$ 0	$ 0	$ 0

Note 7 - Rent Obligation (Det88

Note 7 - Rent Obligation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation			3 years		3 years
Lessee Leasing Arrangements Operating Leases Extension Term			5 years		5 years
Operating Leases, Rent Expense	$ 16,356	$ 15,900	$ 50,106	$ 50,156	$ 66,345	$ 64,753

Note 7 - Rent Obligation - Re89

Note 7 - Rent Obligation - Rent Obligation (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
2,016	$ 9,500	$ 38,000
2,017	39,000	39,000
2,018	$ 3,600	$ 3,000

Note 8 - Related Party Transa90

Note 8 - Related Party Transactions (Details Textual) - USD ($)	Aug. 31, 2015	Feb. 04, 2014	Aug. 31, 2015	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Oct. 24, 2016	Feb. 28, 2014	Jan. 31, 2014
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues		19,231
Stock Issued During Period, Value, New Issues		$ 25,000
Chief Executive Officer [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3
Chief Executive Officer [Member] | Stock Conversion from Series A Convertible Stock to Exchange Units [Member]
Conversion of Stock, Shares Converted	250
Conversion of Stock, Shares Issued	2,778
SOK Partners LLC [Member] | The Convertible Notes [Member]
Debt Instrument, Redemption Price, Percentage			140.00%
Repayments of Related Party Debt			$ 163,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues					66,667		3,804,860
Stock Issued During Period, Value, New Issues					$ 667
Stock Issued During Period, Shares, New Issues	1,666,667			548
Stock Issued During Period, Value, New Issues					$ 13,060,880	$ 2,055,001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								862	862

Note 9 - Retirement Savings P91

Note 9 - Retirement Savings Plan (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100.00%		100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			4.00%		4.00%	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 7,401	$ 7,021	$ 28,196	$ 21,735	$ 39,916	$ 37,730

Note 10 - Supplemental Cash F92

Note 10 - Supplemental Cash Flow Data (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Interest Paid	$ 3	$ 226,960	$ 3	$ 237,121	$ 246,620	$ 47,111

Note 11 - Investment Securiti93

Note 11 - Investment Securities and Other Comprehensive Income (Loss) - Cost and Fair Values of Investment Securities Available-for-sale (Details) - Mutual Fund [Member]	Sep. 30, 2016USD ($)
Cost	$ 572,309
Gross Unrealized Gains	4,579
Gross Unrealized Losses
Fair Value	$ 576,888